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Summary 
 
Recurrent episodes of systemic inflammation are the hallmarks of cryopyrin-
associated periodic syndromes (CAPS), leading to symptoms like fever, urtricaria and 
sensorineural hearing loss. Due to mutations in the NLRP3 gene, encoding for 
cryopoyrin, one of the key components of the NLRP3 inflammasome, patients show 
elevated levels of IL-1β. Previous studies demonstrated that the overactivation of the 
inflammasome resulting in high levels of IL-1β leads to elevated numbers of myeloid-
derived suppressor cells (MDSC). This innate immune cell population is 
heterogeneous and able to suppress T-cell responses, which renders MDSCs key 
players in the balance between innate and adaptive immunity. This led us to the 
hypothesis that MDSCs might be increased in CAPS patients, due to induction of 
NLRP3 inflammasome-dependent factors, being able to influence the disease 
outcome by regulating the autoinflammation. 
Therefore, we investigated the potential role of MDSCs in CAPS by combining ex 
vivo and in vitro studies. We could show that granulocytic MDSCs (G-MDSCs), 
defined as SSChigh, CD66b+, CD33+, CXCR4+, CD16+, CD14- and HLA-DRlow, were 
generally elevated in CAPS patients compared to healthy age-matched controls, 
even under effective anti-IL-1 therapy. Patient’s G-MDSCs were shown to be 
functionally competent as they suppressed polyclonal CD4+ and CD8+ T-cell 
proliferation. Also, cytokine secretion of IFNγ and IL-17 by T cells was decreased 
through G-MDSCs. In addition, we could show that G-MDSCs had a direct anti-
inflammatory effect by suppressing monocytic IL-1β secretion. Furthermore, several 
cytokines and growth factors elevated in CAPS patients could be identified, which 
were already associated with G-MDSC-induction, like GM-CSF and VEGF. These 
findings were corroborated by in vitro studies showing that several IL-1 family 
cytokines and autoinflammation-associated alarmins were able to induce functional 
G-MDSCs, meaning that these identified factors might account for induction of G-
MDSCs in patients besides IL-1β. 
Taken together, an increased G-MDSC population in CAPS might represent a so far 
underappreciated autologous anti-inflammatory mechanism in autoinflammatory 
conditions and might be used for therapeutic approaches in the future. 
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Zusammenfassung 
 
Die Cryopyrin-assoziierten periodischen Syndrome (CAPS) sind definiert durch 
wiederkehrende Episoden systemischer Entzündungsreaktionen, unter anderem 
gekennzeichnet durch Fieber, Hautauschläge und sensorineurale Schwerhörigkeit. 
Die Syndrome haben ihre genetischen Ursachen in Mutationen im Gen für NLRP3, 
welches als Cryopyrin exprimiert wird. Cryopyrin ist einer der Hauptbestandteile des 
NLRP3 Inflammasoms, wodurch die Folge dieser Mutation ein erhöhter Level an IL-
1β ist. Verschiedene Studien konnten zeigen, dass eine Überaktivierung des 
Inflammasoms und somit auch erhöhte IL-1β Sekretion zu einer Induktion von 
myeloiden Suppressorzellen (MDSCs) führt. MDSCs sind eine heterogene 
Zellpopulation des angeborenen Immunsystems und in der Lage T-Zellantworten zu 
supprimieren. Dadurch nehmen MDSCs eine wichtige Rolle im Gleichgewicht 
zwischen angeborener und erworbener Immunität ein. Diese Beobachtungen führten 
uns zu der Hypothese, dass MDSCs in Patienten mit CAPS erhöht sein könnten, 
induziert durch Faktoren, die durch das NLRP3 Inflammasom sezerniert werden. 
Dadurch ist es möglich, dass MDSCs regulierend auf den Krankheitsverlauf von 
CAPS Patienten Einfluss nehmen. 
Hierfür studierten wir die mögliche Funktion von MDSCs in CAPS durch eine 
Kombination von ex vivo und in vitro Experimenten. Wir konnten zeigen, dass 
granulozytäre MDSCs (G-MDSCs), per Definition SSChigh, CD66b+, CD33+, CXCR4+, 
CD16+, CD14- und HLA-DRlow, in CAPS Patienten erhöht sind im Vergleich zu 
gesunden Spendern gleichen Alters. Dies konnte auch für Patienten mit effektiver 
anti-IL-1 Therapie gezeigt werden. Die G-MDSCs der Patienten waren funktionell, 
indem sie die Proliferation von CD4+ und CD8+ T Zellen Dosis-abhängig 
supprimierten. Zusätzlich konnte eine verminderte Zytokinsekretion von IFNγ und IL-
17 gezeigt werden. Darüber hinaus konnten wir eine verminderte Ausschüttung von 
IL-1β durch Monozyten beobachten, was auf eine direkt anti-inflammatorisch 
Wirkung von MDSCs in CAPS Patienten hinweist. In weiteren Experimenten wurden 
verschiedene Zytokine und Wachstumsfaktoren identifiziert, die im Serum der 
Patienten erhöht sind. Hierzu gehören zum Beispiel GM-CSF und VEGF, von denen 
bekannt ist, dass sie G-MDSCs induzieren. Diese Entdeckung wurde in in vitro 
Experimenten vertieft, in denen gezeigt werden konnte, dass Mitglieder der IL-1 
Familie, sowie verschiedene bei Autoinflammation erhöhte Alarmine, in der Lage 
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sind, funktionelle G-MDSCs zu induzieren. Dies bedeutet wiederum, dass neben IL-
1β noch weitere Faktoren für die erhöhte Anzahl an G-MDSCs bei CAPS Patienten 
verantwortlich seien dürften. 
Zusammenfassend konnten wir zeigen, dass CAPS Patienten mehr G-MDSCs 
besitzen als gesunde Kontrollen und dass G-MDSCs somit einen autologen 
Mechanismus der Entzündungsbegrenzung darstellen. Diese Ergebnisse könnten in 
Zukunft für zusätzliche Therapieoptionen autoinflammatorischer Krankheiten von 
Nutzen sein. 
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1. Introduction 
 
1.1 Cryopyrin-associated periodic syndromes (CAPS) 
 
Cryopyrin-associated periodic syndromes (CAPS) are a group of inherited 
autoinflammatory diseases with varying degrees of severity, including familiar cold 
autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS) and neonatal-
onset multisystem inflammatory disorder (NOMID).  
CAPS is a very rare disease with an estimated prevalence of 1 to 10 cases in one 
million (Farasat, Aksentijevich, and Toro 2008), although the assumed prevalence is 
probably higher due to unawareness of physicians and mis- or late diagnosis of the 
disease (Stych and Dobrovolny 2008; Giat and Lidar 2014). Caucasians seem to be 
affected more frequently, but there are no gender preferences (Kummerle-Deschner 
2012).  
CAPS is caused by mutations in the  nucleotide-binding oligomerization domain 
(NOD)-like receptor family, pyrin domain containing 3 (NLRP3) gene coding for 
cryopyrin, which leads to overactivation of the NLRP3 inflammasome, resulting in 
systemic inflammation driven by excessive secretion of interleukin (IL)-1β. 
1.1.1 The NLRP3 inflammasome 
 
Inflammasomes are part of the innate immune defence against pathogens or cellular 
stress and present molecular platforms for the maturation of pro-inflammatory 
cytokines (Martinon, Burns, and Tschopp 2002). The most extensively studied 
inflammasome is the NLRP3 inflammasome. As a multiprotein, intracellular complex 
it leads to the secretion of the proinflammatory cytokines IL-1β and IL-18 in a 
caspase-1 dependent manner. This process is tightly regulated by two steps, namely 
a priming and an activation step, to avoid abnormal stimulation of the inflammasome 
and consequent tissue damage. 
Different ligands, like pathogen-associated molecular patterns (PAMPs), danger-
associated molecular patterns (DAMPs) or pathogens bind to receptors on the cell 
surface and lead to a signal cascade, resulting in activation of nuclear factor ‘kappa-
light-chain-enhancer’ of activated B cells (NFκB) (Bauernfeind et al. 2009), followed 
by the transcriptional upregulation of the IL1B transcript (Hiscott et al. 1993). The 
transcript of IL-18 however is constitutively expressed in most cells (Marshall et al. 
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1999). Besides priming with a Toll-like receptor (TLR) agonist, also proinflammatory 
cytokines like tumor necrosis factor (TNF) are able to induce activation of NFκB 
(Franchi, Eigenbrod, and Nunez 2009). 
After priming, a second signal is required to activate caspase-1, which is able to 
translate the cytokine proforms into their mature forms. This activation step is 
conducted by a large number of different agents, like potassium efflux (Petrilli et al. 
2007; Kahlenberg and Dubyak 2004), reactive oxygen species (ROS) (Cassel et al. 
2008; Cruz et al. 2007; Dostert et al. 2008), crystals (Martinon et al. 2006; Hornung et 
al. 2008) or adenosine triphosphate (ATP) (Mariathasan et al. 2006), whereby the 
whole mechanism has not been solved so far and is still highly debated. Upon 
activation, the NLRP3 complex, consisting of C-terminal leucine rich repeats (LRRs), 
a central nucleotide-binding and oligomerization domain (NACHT) and an N-terminal 
pyrin domain (PYD), oligomerizes. Due to conformational changes, the NLRP3 can 
now recruit the adaptor protein apoptosis-associated speck-like protein containing a 
caspase recruitment domain (CARD) (ASC) via its PYD domain. ASC also contains a 
CARD domain, with which it can in turn bind the CARD of procaspase-1. After 
autocleavage, caspase-1, now in its active form, is able to mature IL-1β and IL-18, 
followed by their secretion into the extracellular space (see figure 1) (Martinon, 
Burns, and Tschopp 2002) 
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Figure 1: The NLRP3 inflammasome 
The NLRP3 inflammasome is a multiprotein, intracellular complex, which leads upon activation, to the 
maturation and secretion of IL-1β and IL-18 in a caspase-1 dependent mechanism. It is activated in a 
two-step model, including priming via e.g. DAMPs or PAMPs, leading to transcriptional upregulation of 
IL-1β, and activation, via ROS, ATP, crystals and K+-efflux. Upon oligomerization of the NLRP3 and 
recruitment of ASC, the active form of caspase-1 matures the proinflammatory cytokines, which get 
secreted in the extracellular space (adapted from Tschopp and Schroder 2010). 
 
 
1.1.2 Genetics and pathogenesis of CAPS 
 
The underlying cause of CAPS is mutations in the NACHT domain of the NLRP3 
gene coding for cryopyrin, located on chromosome 1q44. These mutations are either 
inherited autosomal-dominantly or de novo gain-of-function mutations, latter ones 
especially seen in NOMID (Aksentijevich et al. 2002). Up to date there are about 177 
different sequence variants of the NLRP3 gene known 
(http://fmf.igh.cnrs.fr/ISSAID/infevers/search.php, May 2016), as well as more than 
90 heterozygous mutations which have been associated with CAPS and there is a 
strong correlation between phenotype and genotype. Regardless, carriers of the 
identical mutation sometimes show a heterogeneous phenotype (Levy et al. 2015). 
Around 40% of NOMID patients cannot be associated with a genetic mutation, 
though in most of these patients somatic mosaicism could be identified (Tanaka et al. 
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2011), implicating the involvement of genetic mosaicism in the pathogenesis of 
CAPS. 
Cryopyrin is a member of the nucleotide-binding oligomerization domain-like receptor 
(NLR) family and is crucial for the formation of the NLRP3 inflammasome. As the 
mutation leads to gain-of-function, patients possess an overactivated NLRP3 
inflammasome, leading to high levels of IL-1β, most importantly. As IL-1β is a potent, 
proinflammatory cytokine, its excessive secretion leads to various inflammatory 
symptoms. 
 
 
1.1.3 Clinical manifestation of CAPS patients 
 
CAPS patients suffer from chronic or recurrent episodes of systemic inflammation, 
involving skin, joints, muscles, eyes and the central nervous system (CNS) and are 
commonly associated with progressive sensorineural hearing loss. 
FCAS represents the mildest form of CAPS and is induced upon exposure to cold, 
resulting in a systemic inflammatory response. Besides fever accompanied by 
shivering and urtricaria, patients also develop conjunctival infections as well as 
arthralgia. Patients additionally suffer from daily rashes, fatigue, headache, myalgia 
and conjunctivitis even without a clear trigger. The episodes vary in length and 
severity depending on the length of cold exposure, but normally resolve within 24 
hours (Stych and Dobrovolny 2008).  
The intermediate phenotype of MWS is more chronic, resulting in episodes of fever, 
headache, urtricaria, arthralgia and arthritis (Muckle and Wellsm 1962). In contrast to 
FCAS there is no specific trigger inducing the attacks. The onset of the disease is 
already in the early childhood and is accompanied by progressive sensorineural 
hearing loss (Kuemmerle-Deschner et al. 2013; Biswas and Stafford 2010) as well as 
secondary amyloidosis as a late complication. Latter one can result in proteinuria and 
renal failure (Aganna et al. 2002). 
NOMID, also known as chronic, infantile, neurological, cutaneous and articular 
(CINCA) syndrome, is the most severe form of CAPS and already starts in the 
neonatal phase. It is associated with chronic urtricaria-like rashes, joint-involvement 
like arthropathy (Hill et al. 2007) and arthritis as well as CNS symptoms. Latter ones 
are shown through chronic aseptic meningitis, intracranial pressure, headaches, 
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seizures and goes as far as cognitive and mental deficits (Goldbach-Mansky 2011). 
Patients also evolve a progressive sensorineural hearing loss (Ahmadi et al. 2011) 
and additionally suffer from uveitis, conjunctivitis, optic neuritis and papillary 
involvement (Dollfus et al. 2000). The disease is also present morphologically; 
patients are of short stature, have an enlarged head and a characteristic saddle-back 
nose (Goldbach-Mansky 2011). Additionally, extremities are rather short and thick. 
As NOMID is defined by a neonatal onset accompanied by end-organ damage, there 
is a high mortality among patients, often leading to death before adulthood, 
especially when left untreated (Prieur et al. 1987). 
As symptoms in all CAPS diseases are chronic and often occur unpredictable and 
even daily, life quality of patients is largely impaired, especially due to the chronic 
fatigue and pain patients suffer from. Patients commonly live to avoid exposure to 
cold temperature and are thereby readily compromised in their professional and 
social life (Stych and Dobrovolny 2008). 
 
 
1.1.4 Diagnosis and current treatment options 
 
As CAPS are very rare diseases and symptoms are unspecific and overlap with other 
conditions, diagnosis occurs rather late, also because physicians are frequently 
unaware of the disease. Often, a variety of diagnostic tools is necessary, as there is a 
strong variability of disease severity, making it hard to point out a specific diagnosis. 
Commonly inflammatory markers are assessed (e.g. erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP) and serum amyloid A (SAA)), accompanied by skin 
biopsies and genetic testing for NLRP3 mutations. As the latter one sometimes 
already correlates with the phenotype of the disease, a prediction of the outcome 
might be possible. Additionally, as CAPS is an autosomal-dominant disease, family 
history is taken into account as well as physical examination. Early diagnosis is 
crucial to be able to prevent end-organ damage and reverse symptoms, although not 
all symptoms are reversible, especially bone deformations in NOMID patients. 
Before the discovery of the disease mechanism of CAPS, patients could only be 
treated to ameliorate symptoms with anti-inflammatory drugs. But since the mutation 
and the pathogenesis based on the NLRP3 inflammasome and IL-1β has been 
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revealed, several drugs are on the market, which target IL-1β to supress the 
excessive inflammatory state in patients and avoid organ damage. 
Canakinumab is the most commonly used drug for CAPS patients and shows a very 
high remission rate. It is a human anti-IL-1β monoclonal antibody which is specific for 
IL-1β without cross-reactivity to IL-1α and IL-1 receptor agonist (IL-1RA) (Alten et al. 
2008). Its high half-life of 21 to 28 days makes it possible that injections only have to 
be given every 8 weeks and it leads to a rapid remission of symptoms (Lachmann et 
al. 2009). The European Medicines Agency (EMA) approved Canakinumab for all 
CAPS patients older than 2 years; the Food and Drug Agency (FDA) gave approval 
for the antibody in patients with FCAS or MWS that are older than 4 years. 
Anakinra, a recombinant IL-1RA, was approved in July 2014 by the EMA for all CAPS 
patients older than 8 months. The FDA approved Anakinra for NOMID patients that 
are 4 years or older. This agonist has a half-life of about 4 to 6 hours and has thus to 
be given daily through subcutaneous injections. It blocks the activity of both IL-1α 
and IL-1β and has been shown to be effective in the reduction of daily symptoms and 
proteinuria, as well as in the prevention of cold-induced attacks (Hawkins, Lachmann, 
and McDermott 2003; Hoffman et al. 2004). 
Rilonacept is a fusion protein made up of the extracellular domains of a humanized 
IL-1 receptor, type 1 (IL-1R1) and an IL-1 receptor accessory protein (IL-1RAcP), 
which is fused to the Fc protein of immunoglobulin G1 (IgG1) and functions as an IL-1 
trap, targeting both IL-1α and IL-1β (Stahl, Radin, and Mellis 2009). With a half-life of 
about 6.3 to 8.6 days, it has to be injected subcutaneously once a week, which is an 
advantage over the daily injections of Anakinra. However, the monthly costs of 
Rilonacept are still higher. Rilonacept has been shown to be effective in ameliorating 
symptoms which occur on a daily basis and is well tolerated (Hoffman et al. 2008). It 
is FDA approved for patients with FCAS and MWS older than 12 years. 
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Figure 2: Current treatment options for CAPS patients. 
Treatment for CAPS patients is based on targeting IL-1β to suppress the excessive inflammation in 
the patients. Canakinumab is a fully human monoclonal antibody binding IL-1β specifically. Anakinra 
acts as a recombinant IL-1 receptor agonist, preventing IL-1β and IL-1α to bind to the IL-1 receptor. 
Rilonacept functions as an IL-1 trap. It is a fusion protein made up of the extracellular domains of a 
humanized IL-1 receptor, type 1 (IL-1R1) and an IL-1 receptor accessory protein (IL-1RAcP) fused to 
the Fc protein of IgG1, preventing IL-1β and IL-1α to bind to the IL-receptor (adapted from (Federici, 
Martini, and Gattorno 2013). 
 
 
1.2 Myeloid-derived suppressor cells (MDSCs) 
 
1.2.1 Origin and expansion of MDSCs 
 
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of immature 
myeloid cells (IMCs). They derive from cells in the bone marrow, which – under 
healthy conditions – migrate into the periphery and mature into granulocytes, 
dendritic cells and macrophages. Under certain circumstances though, like cancer, 
infections, inflammation or trauma, this differentiation is blocked, resulting in the 
expansion of MDSCs (see figure 3). 
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Figure 3: Origin and expansion of MDSCs 
Under pathological conditions, MDSCs expand from IMCs in the bone marrow, which normally 
differentiate into granulocytes, dendritic cells or macrophages. This expansion is driven by pathogens, 
cancer, inflammation or trauma. HSC: hematopoietic stem cell: common myeloid progenitor, IMC: 
immature myeloid cell (adapted from (Gabrilovich and Nagaraj 2009). 
 
Expansion and activation of MDSCs is regulated by factors, which can be divided into 
two different groups. First, tumor-derived factors are able to induce expansion of 
MDSCs by stimulating the myelopoiesis and concurrently inhibiting the differentiation 
into mature myeloid cells. These factors include cyclooxygenase-2, prostaglandins 
(Sinha, Clements, Fulton, et al. 2007; Obermajer et al. 2011), growth factors, such as 
granulocyte-macrophage colony-stimulating factor (GM-CSF) (Serafini et al. 2004), 
granulocyte colony-stimulating factor (G-CSF) (Sawanobori et al. 2008), macrophage 
colony-stimulating factor (M-CSF) (Menetrier-Caux et al. 1998), vascular endothelial 
growth factor (VEGF) (Gabrilovich et al. 1998), stem-cell factor (SCF) (Pan et al. 
2008) and IL-6 (Bunt et al. 2007). Also the heat shock protein (Hsp) 72 (Chalmin et 
al. 2010) and the complement factor C5a (Markiewski et al. 2008) have been shown 
to be involved in MDSC expansion. The main signalling cascade activated by these 
factors is the janus kinase (JAK) and signal transducer and activator of transcription 3 
(STAT3) pathway (Gabrilovich and Nagaraj 2009). 
The second group is responsible for activation of MDSCs and include factors deriving 
from activated T cells or tumor stromal cells. Examples are proinflammatory 
cytokines, such as interferon (IFN)-γ (Gallina et al. 2006), tumor growth factor (TGF)-
β (Yang et al. 2008), TNF-α (Hu et al. 2014; Sade-Feldman et al. 2013), IL-1β (Song 
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et al. 2005), IL-4 (Bronte et al. 2003), IL-12 (Heim et al. 2015) and IL-13 (Highfill et al. 
2010), as well as chemokines, like C-C motif ligand 2 (CCL2) (Huang et al. 2007), C-
X-C motif ligand (CXCL) 5 and CXCL12 (Yang et al. 2008). Also TLR agonists 
(Delano et al. 2007) and proinflammatory molecules like S100A8 or S100A9 (Sinha 
et al. 2008) belong to this group, which conducts its signals via STAT1, STAT6 or 
NFκB (Gabrilovich and Nagaraj 2009). 
In addition to soluble factors, MDSCs are controlled by the membrane-bound death-
receptor Fas (CD95), resulting in apoptosis when bound by Fas-ligand on activated T 
cells (Sinha et al. 2011). 
 
 
1.2.2 Subsets of MDSCs 
 
As MDSCs are a very heterogeneous cell population of immature myeloid cells, no 
specific cell marker is known so far. Nevertheless it is possible to distinguish between 
granulocytic (G-MDSCs) and monocytic MDSCs (M-MDSCs). 
MDSCs are commonly defined as expressing the common myeloid marker cluster of 
differentiation (CD) 33, a sialic acid-binding lectin, and the integrin CD11b and being 
negative for myeloid or lymphoid lineage specific markers (CD3, CD19, CD56). Also 
MDSCs show a low expression of the major histocompatibility complex (MHC) class 
II surface receptor human leukocyte antigen (HLA) DR (Almand et al. 2001), but are 
positive for MHC class I. G-MDSCs have additionally been described as CD15+ and 
CD66b+ (Rodriguez et al. 2009), whereby M-MDSCs are positive for CD14 as a 
monocytic marker. Recently, more markers have been assessed for identification of 
MDSCs, including VEGF receptor 1 (VEGFR1) and the α-chain of the IL-4 receptor 
(IL4Rα/CD124) (Mandruzzato et al. 2009), as well as intracellular markers like 
S100A9 (Zhao et al. 2012) and indoleamine 2,3-dyoxygenase (IDO) (Jitschin et al. 
2014; Mougiakakos et al. 2013) for M-MDSCs. Potential other markers for M-MDSCs 
are CD80, CD83 and dendritic cell-specific intracellular adhesion molecule-3-
grabbing non-integrin (DC-SIGN) (Poschke et al. 2010). 
Although a lot of markers already have been assessed in the phenotypic 
identification of MDSCs, no consensus was made so far, which still renders 
identification of MDSCs a challenge and makes it necessary to include functional 
tests (Mandruzzato et al. 2016). 
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1.2.3 Effector functions of MDSCs 
 
The main function of MDSCs is suppression of T-cell proliferation, which is pleiotropic 
as there are many different ways of inhibition (see figure 4). One way of MDSC-
mediated T-cell suppression is depletion of L-arginine from the microenvironment. 
This conditionally essential amino acid serves as a substrate for two different 
enzymes: inducible nitric oxide synthase (iNOS) and arginase. iNOS converts L-
arginine into nitric oxide (NO), while arginase turns L-arginine into urea and L-
ornithine. The depletion of L-arginine leads to a dysregulation of T-cell proliferation, 
as it is needed for expression of CD3ζ (Rodriguez et al. 2002) and upregulation of 
cell cycle regulators, like cyclin D3 or cyclin-dependent kinase 4 (CDK4) (Rodriguez, 
Quiceno, and Ochoa 2007). NO additionally inhibits the expression of MHC class II 
(Harari and Liao 2004), induces T-cell apoptosis (Rivoltini et al. 2002) and blocks 
signalling via JAK3 and STAT5 in T cells (Bingisser et al. 1998).  
Other important factors involved in suppression of T cells mediated by MDSCs are 
ROS (Kusmartsev et al. 2004; Schmielau and Finn 2001). Effects of ROS like 
hydrogen peroxide (H2O2) range from impairment of CD3ζ expression (Otsuji et al. 
1996) to T-cell death (Hildeman, Mitchell, Aronow, et al. 2003; Hildeman, Mitchell, 
Kappler, et al. 2003) and are the main effector functions of G-MDSCs, while M-
MDSCs rather suppress via NO (Movahedi et al. 2008; Youn et al. 2008). 
Alternatively, MDSCs are able to down-regulate L-Selectin (CD62L) on T cells by 
cleavage through expression of a disintegrin and metallopeptidase domain 17 
(ADAM17), weakening the homing of naïve T cells to lymph nodes (Hanson et al. 
2009). In 2010, Srivastava et al. showed that MDSCs also inhibit T cells by depriving 
cysteine from the microenvironment, which is an essential amino acid for T-cell 
activation and function (Srivastava et al. 2010). 
Besides T-cell suppression, MDSCs additionally have the ability to impair the 
development of natural killer (NK) cells and were shown to affect their production of 
IFNγ and cytotoxicity towards tumor cells. This NK-cell inhibition is mainly mediated 
by membrane bound TGF-β1 and the downregulation of natural-killer group 2, 
member D (NKG2D), which is the main activating receptor on NK cells (Elkabets et 
al. 2010; Li et al. 2009; Liu et al. 2007). 
Moreover, as an indirect way of their suppressive action, MDSCs can induce the de 
novo development of regulatory T cells (Tregs), which are forkhead box P3 (Foxp3) 
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positive. Different studies have been published on this topic and show that the 
induction requires cytokines like IFNγ or IL-10 or direct cell-to-cell contact (Huang et 
al. 2006; Yang et al. 2006). This topic is still controversial though, as no clear 
mechanism has been shown so far (Gabrilovich and Nagaraj 2009). 
Lastly, it has also been demonstrated that MDSCs disrupt innate immune responses 
by cross-talk with macrophages, which is cell contact dependent. This results in an 
elevated production of IL-10 by MDSCs and thereby to a decrease of the IL-12 
production by macrophages, which skews immunity towards a type 2 response 
(Sinha, Clements, Bunt, et al. 2007). 
Taken together, MDSCs have various mechanisms to affect immune responses and 
are thereby considered key players in balancing innate and adaptive immunity. 
 
 
Figure 4: Pleiotropic functions of MDSCs 
MDSCs are able to suppress T-cells through various effector mechanisms, like ROS, NO, depletion of 
L-arginine and cysteine as well as down regulation of L-selectin on T cells. Additionally, MDSCs can 
inhibit NK cells via membrane-bound TGF-β1. Besides suppression, MDSCs can induce regulatory T 
cells via IL-10 or IFNγ. They also interact with macrophages by increasing their secretion of IL-10, 
leading to a decreased IL-12 production of macrophages, resulting in a promoted Th2 response 
(adapted from (Gabrilovich, Ostrand-Rosenberg, and Bronte 2012). 
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1.2.4 MDSCs in pathological conditions 
 
MDSCs have first been described in 1964 in tumor-bearing mice (Lappat and Cawein 
1964), further described as natural suppressor cells in the 1980’s (Maier, Holda, and 
Claman 1989; Strober 1984) until they were named MDSCs in 2007 (Gabrilovich et 
al. 2007). Most studies on MDSCs have been published in correlation to cancer, 
showing an expansion of this suppressive cell population and opening perspectives 
for new cancer therapies. But recently, MDSCs have also been associated to 
bacterial (Tebartz et al. 2015), fungal (Rieber et al. 2015) and parasitic (Goni, 
Alcaide, and Fresno 2002; Voisin et al. 2004) infections as well as to acute and 
chronic inflammation and autoimmune diseases (Haile et al. 2008; Marhaba et al. 
2007; Zhu et al. 2007). Additionally, MDSCs are known to be elevated in patients with 
traumatic stress (Makarenkova et al. 2006), sepsis (Delano et al. 2007) or after 
transplantation (Dugast et al. 2008). This variety shows that MDSCs expand 
commonly in different pathological conditions and are important in many distinct 
settings, making it even more important to study this cell population, not only 
because they show such pleiotropic and diverse effector functions. Depending on the 
pathological environment, MDSCs can have a beneficial or harmful influence. 
Numerous studies show that MDSCs have a negative influence on antitumor 
immunity, as they inhibit immunosurveillance and contribute to tumor progression 
(Almand et al. 2001; Bunt et al. 2006; Nagaraj and Gabrilovich 2008). Nevertheless, 
as they act anti-inflammatory, they are considered beneficial when it comes to 
autoinflammatory diseases or infections. 
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2. Aim of the study 
 
In recent years, MDSCs have gathered a substantial amount of attention in terms of 
one of the immunotherapeutic strategies for cancer treatment, as well as in settings 
of inflammatory diseases. Several publications have shown that MDSCs get induced 
upon inflammation. Importantly, IL-1β has been associated with MDSC induction.  
As IL-1β is the driving proinflammatory factor in CAPS patients, we aimed to address 
the question if MDSCs are induced in CAPS patients. Moreover, we were interested if 
MDSCs also affect other immune cell types important in these autoinflammatory 
diseases besides CD4+ and CD8+ T cells. Therefore we evaluated the influence of 
MDSCs on Th17 cells, which have been associated to autoinflammation previously. 
Also, to assess the influence of MDSCs on the main cell type responsible for the 
excessive inflammation in CAPS patients, monocytes and their secretion of IL-1β 
were investigated. Furthermore, we tried to elicit other inflammation-associated 
factors that might be involved in MDSC induction not only in CAPS patients but also 
in healthy individuals.  
Our findings provide new insights into the autologous anti-inflammatory response 
mechanism in CAPS and might be beneficial in developing new treatment options in 
addition to the currently available standard therapies. 
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3. Discussion 
 
The central aim of this study was to investigate the presence and role of MDSCs in 
an autoinflammatory setting, particularly in CAPS. Until now, MDSCs have been 
thoroughly investigated and characterised in different forms of cancer, both in mice 
and human. Also knowledge about MDSCs in other pathologies, such as bacterial, 
parasitic and fungal infections or autoimmune diseases was broadened in the last 
years. Nevertheless, there is still scarce information when it comes to 
autoinflammatory diseases, especially in the human system. As it is known that 
inflammation and notably IL-1β lead to induction of G-MDSCs, we hypothesized that 
G-MDSCs are induced in the autoinflammatory setting of CAPS. To further 
investigate this, we combined patient data and in vitro studies to analyse the role of 
G-MDSCs and their influence on different cell types, including T-cell subsets and 
monocytes. Thereby we could show that G-MDSCs present a direct anti-inflammatory 
mechanism, which might be useful for the development of new therapies. In this part 
the difference of the identified cells compared to neutrophils will be discussed as well 
as how these cells are induced in the setting of CAPS. Furthermore, their influence 
on different T-cell subsets and on monocytes will be elucidated as well as their 
possible influence on other cell types. Lastly, the options of a therapeutic use of 
MDSCs in CAPS patients will be evaluated. 
 
 
3.1 Definition of MDSCs – comparison to neutrophils 
 
MDSCs are characterized to be lineage negative and as this cell population is so 
heterogeneous, there is no exclusive marker to phenotype MDSCs further, especially 
human ones. Therefore it is important to include functional assays, like T-cell 
proliferation assays, to assess the identity of MDSCs.  
This becomes critical as G-MDSCs are very similar to neutrophils in their morphology 
and phenotype, as for example both are positive for CD66b, CD33, CD16 or CXCR4. 
Until now there is no reliable marker to distinguish neutrophils from G-MDSCs, as 
there is no consensus in the literature for the use of markers and some findings are 
even contradictory (Mandruzzato et al. 2016; Pillay et al. 2013). So an exclusive 
marker would be ideal in order to distinguish both cell types as well as a definition of 
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the differences between these two cell types on a molecular and functional level 
(Dumitru et al. 2012). Morphologically, the gold standard of neutrophil identification is 
done via May-Grünwald-Giemsa staining. Upon staining, neutrophils are seen under 
the microscope as cells with a nucleus, which is either formed like a band or (hyper-) 
segmented. Additionally, the cytoplasm is of light pink or purple with visible granules. 
In studies where the morphology of neutrophils and G-MDSCs was compared, G-
MDSCs are mostly shown as young and immature cells, which are suppressive in 
contrast to the mature neutrophils (Greifenberg et al. 2009). Nevertheless there are 
also publications presenting data where G-MDSCs with a more mature morphology 
similar to neutrophils are suppressive (Dumitru et al. 2012). Taken together, 
morphology alone is not suitable for identification of immunosuppressive G-MDSCs 
and distinction from neutrophils. In this study we saw a similar morphology of G-
MDSCs and neutrophils, following the concept of G-MDSCs being a rather 
heterogeneous cell population without a clear demarcation between immature and 
mature cells. 
To find differences between the two very close cell types it is worthy to look into their 
gene expression profile. One study from Fridlender et al. found that G-MDSCs have a 
lower messenger ribonucleic acid (mRNA) expression of granule proteins, 
nicotinamide adenine dinucleotide phosphate (NADPH) complex subunits and 
peroxidases and a higher expression of arginase 1 (Fridlender et al. 2012). 
Moreover, Youn et al. revealed an upregulated expression of myeloperoxidase 
(MPO) and proteins involved in the cell-cycle of G-MDSCs, whereby neutrophils 
showed an upregulation of different cytokines, chemokines and proteases (Youn et 
al. 2012). Nevertheless differences in gene expression profiles cannot be used for 
isolation of these cells.  
As G-MDSCs are of low density, they are found in the mononuclear layer when blood 
is separated by density centrifugation, whereby neutrophils have higher density and 
can be found in the pellet, on top of the erythrocytes. Still, neutrophils can 
degranulate and thereby loose some density ending up in the fraction of peripheral 
blood mononuclear cells (PBMCs), mixing themselves with G-MDSCs (Bryk et al. 
2010). Furthermore, activation of neutrophils can lead to an acquired immune 
suppression, for example through release of intracellular arginase 1 resulting from 
induction of exocytosis or neutrophil death (Rotondo et al. 2009). This results in an 
inhibition of T-cell activity, e.g. through a decreased expression of the CD3ζ chain of 
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the T-cell receptor (Munder et al. 2006). As activation of neutrophils can lead to 
suppression, G-MDSCs are in some publications defined as a subtype of neutrophils 
(Rodriguez et al. 2009; Pillay et al. 2013). 
In this study we identified G-MDSCs as SSChigh, CD66b+, CD33+, CXCR4+, CD16+, 
CD14- and HLA-DRlow, with a mature morphology and additionally showing their 
suppressive capacity compared to conventional neutrophils. These functional tests 
include T-cell proliferation tests with carboxyfluorescein succinimidyl ester (CFSE)-
stained T cells, cytokine release by T cells as well as assays to assess the effector 
molecules released by G-MDSCs.  
The comparison of G-MDSCs to neutrophils can in the same way be applied to M-
MDSCs and monocytes, which are also very similar as they both express, besides 
others, the monocytic marker CD14 and are morphologically very similar. But as in 
autoinflammation G-MDSCs are the more relevant subtype of MDSCs, the focus is 
laid on them instead of on M-MDSCs, which might be of higher relevance in cancer 
settings (Montero et al. 2012). 
 
 
3.2 Induction of MDSCs 
 
CAPS patients have an underlying mutation leading to elevated inflammasome 
activity. The high levels of IL-1β secreted mainly by monocytes lead to an excessive 
autoinflammation in these patients. We could show that IL-1β also induces the 
generation of G-MDSCs in vitro from immature myeloid cells by binding to the IL-1 
receptor. This leads to the activation of the JAK-STAT pathway resulting in 
upregulation of ROS and arginase 1, which get released and in turn are able to 
supress T-cell proliferation. Also G-MDSCs can have direct cell-to-cell contact with T 
cells, thereby adding to the suppression. Which receptors are relevant for this has not 
been addressed so far in the human setting, but inhibitory receptors, like 
programmed cell death protein 1 (PD-1) or cytotoxic T-lymphocyte-associated protein 
4 (CTLA4) seem likely (Ioannou et al. 2012). Especially PD-1 seems to be involved in 
T-cell impairment by MDSCs, which could be seen in mice (Liu et al. 2008) as well as 
in colorectal cancer patients (Zhang et al. 2013). Also lymphocyte-activation gene 3 
(LAG3) has been discussed for its involvement in MDSC-mediated T-cell suppression 
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as it is up-regulated, together with PD-1, on T cells after co-culture with MDSCs 
(Pinton et al. 2015).  
Through this inhibition, T cells, as important effector cells in this autoinflammatory 
setting, are restricted in some way, but as IL-1β levels are very high and the 
inflammation in the patients is very severe, the little amount of G-MDSCs alone is not 
sufficient to fight the disease.  
Noteworthy is that the patients in this study are under the treatment of Canakinumab, 
meaning that they already show less IL-1β compared to the naïve state. As there are 
still more G-MDSCs compared to healthy age-matched controls seen in the flow 
cytometry analysis, other factors must additionally account for G-MDSC induction in 
these patients. As seen by multiplex analysis and enzyme-linked immunosorbent 
assay (ELISA), GM-CSF is elevated in the patients. GM-CSF as an already 
established G-MDSC-inducing factor is used commonly as a positive control in 
MDSC in vitro studies (Lechner, Liebertz, and Epstein 2010; Rieber et al. 2013). 
Besides GM-CSF, VEGF is another candidate elevated in the serum of patients and 
known to be a G-MDSC-inducing factor, as it blocks the differentiation of dendritic 
cells while driving the accumulation of MDSCs (Gabrilovich et al. 1998). Kujawski et 
al. also showed that MDSCs themselves secrete VEGF, leading to an autocrine 
feedback loop which sustains the accumulation of MDSCs (Kujawski et al. 2008). As 
both growth factors could be shown to be independent of IL-1β by ELISA of sera of 
patients before and after therapy with Canakinumab, they are possible candidates for 
inducing G-MDSCs in the absence of IL-1β. Fibroblast growth factor (FGF) is 
elevated as well, even under Canakinumab treatment, but when tested in vitro for G-
MDSC stimulation no effect could be seen, meaning that FGF alone is not 
responsible for MDSC induction. This has already been published in a broader 
context by Keller et al. in 2008 showing that FGF is secreted in an NLRP3-dependent 
manner, which is however independent from catalytic caspase-1 activity and IL-1β 
(Keller et al. 2008). Also the chemokines monocyte chemotactic protein (MCP)-1 and 
macrophage inflammatory protein (MIP)-1α (CCL2 and CCL3) were shown to be 
elevated in the serum of patients, but were unable to induce suppressive G-MDSCs 
in vitro. In the case of IL-8, which has also been shown to be elevated in patient’s 
sera, its concentration goes down concurrently with IL-1β under Canakinumab 
treatment, making it not a relevant candidate for G-MDSC induction, which also could 
be shown through in vitro stimulation assays. Furthermore, other IL-1 family 
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members could be shown to be able to induce G-MDSCs in vitro, including IL-18 and 
IL-1α. Especially IL-18, which is also cleaved by caspase-1 upon NLRP3 
inflammasome activation, seems a legit candidate. Additionally Lim et al. showed in 
2014 that IL-18 is able to induce MDSCs in mice (Lim et al. 2014). Both cytokines 
were validated in functional assays in vitro and proved to induce suppressive G-
MDSCs to at least the same extent as IL-1β. 
Besides the discussed and in this study further investigated factors, other 
inflammation-associated factors can be considered to be responsible for G-MDSC 
induction. This includes several pro-inflammatory cytokines like IFNγ (Gallina et al. 
2006) or TNF-α (Hu et al. 2014; Sade-Feldman et al. 2013). Not published data from 
our laboratory shows that both cytokines are able to induce suppressive G-MDSCs 
which is concordant with the literature. Nevertheless, so far it has not been shown if 
these cytokines are also elevated in CAPS patients. Further studies in our laboratory 
could not identify any other relevant G-MDSC-inducing factor being responsible for 
induction of the suppressive cells in the setting of CAPS. 
Preliminary data indicate that G-MDSCs are also increased in other autoinflammatory 
diseases, including tumor necrosis factor receptor-associated periodic syndrome 
(TRAPS), familial Mediterranean fever (FMF) and periodic fever, aphthous stomatitis, 
pharyngitis and adenitis (PFAPA), which might give a hint for a common mechanism 
of counterregulation in autoinflammatory diseases. Additionally this could provide a 
rationale for the observed strong periodicity of these syndromes. Upon inflammation, 
G-MDSC generation would be induced from myeloid progenitor cells in the bone 
marrow for several days to weeks. In turn this would lead to a decreased 
inflammation, resulting in a disappearance of G-MDSCs over certain days due to 
fading inflammatory stimuli. When inflammation rises up again, a new cycle of 
progenitor cell differentiation can start. 
These findings, especially the elevated growth factors and chemokines discussed 
above, might point to a subclinical inflammation in CAPS patients even under anti-IL-
1 therapy. Therefore, these factors together with increased numbers of G-MDSCs 
may become valuable disease markers. To further assess this, larger longitudinal 
studies are needed for a comprehensive evaluation of elevated factors in patients 
and their relevance in G-MDSC induction. Nevertheless one has to keep in mind that 
some of these factors already have been associated with chronic disease 
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manifestation, for example FGF with organ fibrosis or VEGF with arteriosclerosis 
(Ban and Twigg 2008; Celletti et al. 2001).  
 
 
3.3 Effect of MDSCs on different T-cell subsets 
 
Through the inflammatory environment in the patients, the adaptive immune 
response is stimulated and contributes further to the inflammatory state. As the key 
cytokine IL-1β is of pleiotropic nature, its release also leads to the proliferation of T 
cells and their production of cytokines. As the process of inflammation is very broad, 
all types of T cells are stimulated. It has been shown that T cells are considerably 
skewed towards the highly inflammatory subtype of T helper (Th) 17 cells, a 
proinflammatory CD4+ T-cell subset, in CAPS patients (Lasiglie et al. 2011). This is 
due to the high levels of IL-1β, as it is the key cytokine for Th17 differentiation in 
concert with IL-23, which is also elevated in the serum of patients in an IL-1β 
dependent manner (Kryczek et al. 2007; Sutton et al. 2006). In this study we could 
also see an effect of G-MDSCs on the Th17 cells as the secretion of IL-17 was 
significantly decreased by patients’ G-MDSCs. A study from 2010 has shown that IL-
17 also has an effect on MDSCs as they decrease in IL-17-deficient mice what can 
be reversed when IL-17 is administrated again (He et al. 2010). If this is a direct 
effect or an indirect, as IL-17 also triggers the production of IL-6, leading to activation 
of STAT3 and thereby inducing MDSCs, is not known so far (Wang et al. 2009). 
Nevertheless, some studies also show that MDSCs are able to induce Th17 cells by 
producing IL-6 and TGF-β (Chatterjee et al. 2013) or recruiting them by production of 
CCL4, which is a chemoattractant for Th17 cells (Ortiz et al. 2015). So apparently 
MDSCs and Th17 cells have a complex reciprocal relationship, which is probably 
influenced by several other factors as well as the microenvironment, making it 
necessary to perform more in depth studies to get a conclusive picture. 
Besides suppression of the Th17 response we could also see an effect of G-MDSCs 
on the proliferation of CD4+ T cells. As T-cell response in CAPS patients is, as 
mentioned above, skewed towards a Th17 response, one can speculate that most T 
cells differentiate into Th17 cells and only lower amounts into Th1 and Th2 cells. 
Along with the proliferation of CD4+ T cells, G-MDSCs are also affecting the 
proliferation of CD8+ T cells. These observations show that G-MDSCs have an 
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ubiquitary effect on T cells in CAPS patients. A more thorough investigation of the 
preliminary data is yet needed to clarify this. 
As G-MDSCs showed to suppress proliferation of T cells as well as their secretion of 
IFNγ and IL-17, they might act as a physiological anti-inflammatory mechanism able 
to dampen the inflammation by dampening the T-cell response and also 
counteracting the dysregulated T-cell balance towards Th17. 
In turn, recent studies reported that T cells also have an effect on MDSCs, as already 
discussed for Th17 cells above. Pinton et al. published data, where they show that 
there is an interplay between MDSCs and T cells, involving IL-10. Thereby MDSCs 
get active when in contact with activated T cells, while they stay harmless in the 
presence of resting T cells (Pinton et al. 2015). Similar results were given by another 
study, where Th1 cells were shown to induce MDSCs in mice (Cripps et al. 2010). 
Also Th2 cells have been implicated in having a direct effect on MDSCs (Nagaraj, 
Youn, and Gabrilovich 2013).  
In summary, there is a complex relationship between MDSCs and T cells, which 
seems to be bidirectional. In our studies we did not investigate the influence of T cells 
on MDSCs, while it is still important to keep in mind for the further evaluation of the 
clinical use of MSDCs in CAPS patients. 
 
 
3.4 Effect of MDSCs on monocytes 
 
In the inflammatory setting of CAPS patients, monocytes are the driving cells 
secreting IL-1β and thereby fuelling the inflammation in these patients. In this study 
we asked the question whether G-MDSCs also have an effect on monocytes, as this 
has not been studied so far. We could show that G-MDSCs have indeed an effect on 
monocytes by dampening their release of IL-1β and thereby directly acting anti-
inflammatory. This would mean that there is a direct negative feedback loop of 
MDSCs on the inflammation and not only an indirect one by inhibiting T-cell 
proliferation.  
This observation, together with the effect of G-MDSCs on T cells leads to a complex 
picture of the relationship between the different cell types investigated. This is 
summarized in figure 5. As discussed above, inflammation fuels G-MDSC expansion 
mainly through IL-1β produced by monocytes. Inflammation also leads to the 
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engagement of T cells, leading to a reinforced inflammatory state. In turn, G-MDSCs 
dampen the inflammation by suppressing monocytes and T cells, thereby also 
reducing their own expansion as the activating stimuli of the inflammation go down.  
 
 
Figure 5: Complex relationship of cells in the inflammatory setting of CAPS. 
Monocytes secrete IL-1β, thereby fuelling the inflammation. Additionally IL-1β, besides other factors, 
induces T cells, which further enhance the inflammatory state in the patients. To counteract the 
inflammation, G-MDSCs, which are also induced by IL-1β and other factors, act anti-inflammatory by 
either suppressing monocytes, thereby dampening the IL-1β secretion or by suppression of T cells. 
 
How G-MDSCs directly affect monocytes and which other effects are involved is not 
known, but one can speculate, based on a paper from Sinha et al. from 2007 that 
there is a cross-talk between G-MDSCs and macrophages, which is cell-contact 
dependent (Sinha, Clements, Bunt, et al. 2007). This cell-contact results in a higher 
secretion of IL-10 by G-MDSCs and a dampened IL-12 secretion by macrophages, 
leading to a shift towards a type 2 response, thereby also working against the 
inflammatory Th1 and Th17 response. This could also add to the anti-inflammatory 
properties of the G-MDSCs in the setting of CAPS. Nevertheless, more studies have 
to be performed to address these questions in more depth.  
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3.5 Effect of MDSCs on other cell types 
 
As the inflammasome is not only formed in monocytes, but also in other myeloid 
cells, it is possible that G-MDSCs also have an effect on those cells. For example, 
neutrophils possess an inflammasome as well (Bakele et al. 2014) and might be 
affected by G-MDSCs. One has to keep in mind though that G-MDSCs and 
neutrophils are very similar to one another, as discussed above, what makes it hard 
to see an effect of one cell type on the other. Some experiments regarding this 
question have already been performed in our lab, unfortunately without success. This 
was mainly due to the similarity of the cells and to their different life spans in culture, 
as neutrophils cannot be kept in culture that long, and G-MDSCs need some time to 
fulfil their suppressive function.  
Also dendritic cells (DCs) might be a possible target or interaction partner for G-
MDSCs. This has already been addressed in some publications, making it relevant 
for further studies also in correlation to CAPS patients, as DCs possess a NLRP3 
inflammasome and are able to secrete IL-1β. Additionally they take up antigens for 
procession and present them to T cells as antigen-presenting cells (APCs). Thereby 
DCs might be involved in the inflammation process in the patients. In the context of 
cancer it has already been shown that DCs are impaired in their maturation and 
function. Some publications point towards the fact that this might be due to arising 
MDSCs, leading to the conclusion that there is an interaction between the two cell 
types (Greifenberg et al. 2009; Hu et al. 2011). 
Another cell type, which might be involved in the inflammatory process and being 
influenced by MDSCs are NK cells. So far there is not a lot of data concerning NK 
cells and inflammation and already published data is rather contradictory, as NK 
cells, depending on the model system, can add to the inflammation, but also lead to 
an amelioration of it. Also their contribution in CAPS has not been investigated so far. 
Nevertheless it has been shown that MDSCs influence NK cells by reducing their 
cytotoxic efficacy (Liu et al. 2007). This effect is increased through inflammation 
(Elkabets et al. 2010). Studies giving insights into the role of NK cells in CAPS and 
their relationship towards MDSCs have to be performed in order to draw conclusions. 
MDSCs are the regulatory cell type of the innate part of immunity, but besides 
MDSCs, the adaptive immunity provides Tregs to fulfil this job. It might be interesting 
to investigate this cell type in CAPS patients, as Tregs might help or work together with 
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MDSCs to dampen the excessive inflammation in these patients. Unfortunately there 
is no data on Tregs in CAPS so far. Still, it has been shown that a distinct subtype of 
Tregs, namely Foxp3- type 1 regulatory (Tr1) cells, are able to suppress the NLRP3 
inflammasome by secreting IL-10 (Yao et al. 2015). Concerning the interaction of 
MDSCs with Tregs it has been shown that they might have a reciprocal relationship as 
they induce each other, which is regulated by IL-10 (Fujimura, Kambayashi, and Aiba 
2012; Serafini et al. 2008; Huang et al. 2006). But also here, like for the NK cells, no 
conclusion can be drawn as to whether these cells play a major part in CAPS. Still 
this would be worth investigating, as Tregs might add to the immunosuppressive effect 
together with MDSCs. 
Taken together, MDSCs help to dampen the inflammation in CAPS patients in 
various ways. Firstly, they directly act anti-inflammatory by suppressing IL-1β 
secretion by monocytes. Secondly, MDSCs suppress T-cell proliferation and cytokine 
secretion through their effector molecules. And lastly, one can speculate that they 
also influence the T cells indirectly via DCs by impairing their function, as the major 
task of DCs is to activate T cells by presenting antigens to them, which is 
complemented by secretion of cytokines inducing T-cell differentiation (IFNy, IL-23) 
(Ostrand-Rosenberg et al. 2012). An involvement of neutrophils, NK cells or Tregs is 
also possible, but at this point, due to too little or unavailable data, no certain 
conclusions can be drawn. 
 
 
3.6 Treatment options 
 
In addition to the different anti-IL-1 treatments, namely Canakinumab, Anakinra or 
Rilonacept, G-MDSCs could be used as supplementary cell-based therapy. 
Especially in very severe cases or in specific complications, which do not respond to 
conventional therapies, the addition of G-MDSCs might help to further dampen the 
inflammation in these patients. Thereby in vivo generation or ex vivo expansion of the 
cells, followed by an adoptive transfer, would be possible.  
Several studies suggest the use of GM-CSF and or G-CSF for the generation of 
MDSCs as it has been shown that the increased production of these growth factors 
by tumors is linked to an expansion of MDSCs (Bronte et al. 1999; Abe et al. 2010; 
Shojaei et al. 2009). It already has been shown that this might be applicable for 
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therapeutic uses. For example Zahorchak et al. could show that the frequency of 
MDSCs can be increased in vivo in primates through sequential injection of GM-CSF 
and G-CSF (Zahorchak et al. 2016). Also one could use different combinations of 
stimuli together with GM-CSF, as shown by Lechner et al. in 2010. In this study, 
PBMCs are used to generate MDSCs and also different combinations of stimuli are 
used, which could be also applied here (Lechner, Liebertz, and Epstein 2010).  
Besides from PBMCs, MDSCs can also be induced from bone marrow (BM) cells. 
Marigo et al. developed a method to rapidly induce MDSCs by adding GM-CSF, G-
CSF an IL-6 to BM cells (Marigo et al. 2010). A similar approach was used by Highfill 
et al. as they use GM-CSF and G-CSF and then add IL-13 to the BM cells of mice 
leading to the generation of M-MDSCs with an arginase 1-dependent suppression 
(Highfill et al. 2010). 
In a more clinical setting, different groups have established methods to generate 
MDSCs to treat Graft-versus-host disease (GvHD). Joo et al. showed that G-CSF 
leads to the induction of MDSCs and thereby to the prevention of GvHD (Joo et al. 
2009). This has been deepened by another study, where it was shown that functional 
MDSCs expand in the peripheral blood of G-CSF-mobilized donors, with the capacity 
to regulate alloreactive T-cell responses in vitro (Luyckx et al. 2012). Additionally, 
Adeegbe et al. performed studies, where MDSCs were induced in vivo with G-CSF 
prolonging skin allograft survival in mice (Adeegbe et al. 2011). Another advantage of 
the two growth factors is that they are already available and used therapeutically. 
GM-CSF is used as Sargramostim, while G-CSF is given as Filgrastim to treat 
neutropenia after chemotherapy or BM transplantation (Mehta, Malandra, and Corey 
2015). 
Besides GM-CSF and G-CSF, several other stimulants were used by different groups 
to induce MDSCs in vivo or ex vivo for adoptive transfer. A study from 2015 showed 
that cannabidiol, a major component of Cannabis, is able to induce an 
immunosuppressive population of MDSCs in mice (Hegde et al. 2015). Morecki et al. 
presented data where MDSCs could be induced in mice through CpG 
oligodeoxynucleotide administration, leading to the suppression of alloreactivity and 
protection against the development of GvHD in the recipient after adoptive cell 
transfer (Morecki et al. 2008). In the context of transplantation, there are different 
reports about MDSCs, which were generated in vivo or in vitro and adoptively 
transferred, and which were able to inhibit allograft rejection. Zhang et al. generated 
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MDSCs from transgenic immunoglobulin-like transcript 2 (ILT2) mice. ILT2 is an 
immunosuppressive receptor, binding to HLA-G, a human immunosuppressive non-
classical MHC molecule. The adoptive transfer of these MDSCs led to a longer graft 
survival in the recipients of an allogeneic skin transplant (Zhang et al. 2008). A study 
from 2009 injected mice with lipopolysaccharide (LPS) to generate MDSCs and 
transferred them to skin transplanted mice, resulting in delayed allograft rejection (De 
Wilde et al. 2009).  
An already established therapy, namely extracorporal photopheresis (ECP), is used 
in GvHD patients, where it was shown that this treatment leads to the induction of 
immunosuppressive G-MDSCs (Rieber et al. 2014). ECP is a leukapheresis-based 
approach using psoralen and ultraviolet (UV) radiation leading to immunomodulation, 
which is successfully used in T cell-mediated diseases (Edelson et al. 1987). 
Nevertheless it is not understood how ECP exactly modulates the immune system 
(Knobler et al. 2009).  
Taken together, there are already some possibilities for the clinical use of MDSCs, 
but as most studies have not been performed in a human setting and also not in an 
autoinflammatory setting, several points have to be discussed in order to be able to 
decide which option would be more feasible. Important is to choose the best course 
of treatment for the respective disease. Ex vivo versus in vivo generation of MDSCs 
for example. Which stimulant is the best to generate immunosuppressive MDSCs of 
the right subtype? Here the phenotype should be evaluated to secure similarity 
between generated and naturally occurring MDSCs. In the case of an adoptive 
transfer of ex vivo MDSCs, from which cells should MDSCs be generated from, 
PBMCs or BM cells? Should the transfer be autologous or allogenic? How many cells 
should be given to the patients, how often and by which route of administration? 
Latter one is especially a question concerning life span of the MDSCs in the patients, 
of their in vivo fate and their continuous functionality. Also possible side effects like 
the susceptibility to infections or tumors in the case of CAPS patients have to be 
taken into account.  
As for GM-CSF one has to keep in mind that it has very broad effects and does not 
lead to an isolated induction of MDSCs. It has been shown that the overexpression of 
GM-CSF leads to a severe inflammation what would possibly add to the already 
existing inflammation in the patients (Shi et al. 2006). Additionally data from animal 
models suggest that in certain inflammatory and/or autoimmune diseases the 
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depletion of GM-CSF is beneficial (Hamilton 2008). GM-CSF is furthermore used as 
a potent adjuvant and thereby leading to the induction of other immune cells, like T 
cells, what would again counteract the intended immune suppression (Disis et al. 
1996). To address these issues, more thorough studies have to test the usefulness of 
GM-CSF as treatment in CAPS patients to evaluate possible side effects, especially 
since in some inflammatory diseases the administration of GM-CSF even seems 
beneficial (Hamilton 2008). 
Concerning the immunosuppressive function of MDSCs, Koehn et al. showed that it 
can be lost due to inflammasome activation of the MDSCs after adoptive transfer into 
GvHD mice opting rather for in vivo generation of these cells. Nevertheless this could 
be counteracted through genetic alteration of the MDSCs making them unable to 
express ASC. Until in vivo approaches to inhibit the inflammasome activation of 
MDSCs are available, multiple doses of MDSCs can be used to sustain suppression 
(Koehn et al. 2015).  
Another problem for the in vitro generation might be the amount of cells one can 
generate or what cell number is needed, respectively. An example where adoptive 
transfer of cells is performed is mesenchymal stem cells (MSCs). These mesoderm-
derived multipotent stem cells have immunomodulatory capacities and have shown to 
be effective in the treatment of GvHD (Le Blanc et al. 2004). Most clinical trials 
evaluating MSCs for therapeutic purposes used a dose of 0.4-10 x 106 cells per 
kilogram of body weight (Chen and Hou 2016). To achieve this many cells, it is of 
great need to have a protocol to generate a considerable amount of 
immunosuppressive MDSCs. Certainly this depends on the cells used for the 
generation. PBMCs are surely easier to obtain than BM cells. Another factor enabling 
high cell numbers is the use of allogeneic donors, as here a rapid mass production 
would be possible in contrast to the autologous setting. This would be accompanied 
by lower costs and the possibility to use young healthy donors, which might yield 
cells with higher efficacy. Nevertheless it has been shown, in the case of MSCs, that 
cells from autologous donors are more potent (Togel et al. 2009). If this is also the 
case for MDSCs needs to be evaluated. In summary one can conclude that a lot of 
different factors have to be taken into account when establishing a cell-based therapy 
for special indications in CAPS patients. For a conclusive decision which way would 
be the best, further studies and of course clinical studies are needed, to evaluate all 
discussed factors. 
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Supplemental Table S1
all: [pg/µl]
PDGF IL-1b
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
12316,62 11833,66 17126,18 0 1,6 14,94
10275,33 19285,2 19877,15 0 2,88 9,17
13277,79 14144,61 18939,39 2,39 2,69 8,86
13209,14 8002,62 9341,82 1,59 0 5,28
18247,06 13895,48 17366,16 2,75 0 13,4
18794,7 18267,49 14,88 16,26
8973,8 7053,68 2,21 0
16943,5 11729,23 2,59 4,46
18781,54 12951,29 8,16 2,41
19467,32 17543,17 0 15,14
6279,98 11525,01 1,45 4,87
13294,69 13431,04 2,17 4,28
19340,62 16905,79 13,99 18,62
19663,88 20910,67 3,52 6,28
12918,75 5349,08 2,7 4,24
9473,19 4501,52 2,56 1,04
7469,97 18576,76 0 5,77
18520,67 8308,35 4,38 7,87
8210,27 14725,17 1,63 7,51
9950,5 16545,98 3,59 11,39
9957,07 15802,93 8,89 52,44
18226,67 55,26
Median
13209,14 13595,085 15802,93 1,59 2,64 7,51
IP-10 IL-1ra
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
443,46 583,09 950,09 24,53 93,16 119,96
234,19 206,09 410,78 40,82 175,98 186,54
286,26 217,99 371,53 140,25 89,91 128,89
851,2 319,07 479,6 118,34 85,85 152,43
599,35 1254,24 752,39 106,97 42,68 107,78
833,2 967,52 151,62 249,18
576,22 514,04 78,53 17,64
284,41 348,63 93,16 59,81
831,01 577,22 45504,42 19242,75
824,6 835,87 186,88 263,84
409,19 853,29 78,53 166,24
864,61 632,57 76,91 73,65
990,82 991,01 250,81 111,03
843,77 368,15 143,5 171,11
748,64 1125,11 141,88 35,28
1612,69 5323,36 125,64 24,52
305,51 876,67 31,64 127,27
896,8 522,9 109,41 88,29
494,8 369,9 77,72 115,9
459,23 938,34 282,6 182,48
714,43 507,97 319,33 68,77
721,96 94,79
Median
443,46 718,195 632,57 106,97 102,1 119,96
IL-2 IL-4
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
0 2,65 5,03 5,87 5,58 6,1
0 6,28 11,12 5,01 11,87 11,17
4,35 7,83 9,99 9,54 9,46 9,92
0 0 7,26 7,94 4,44 9,52
46,01 0,11 5,32 9,15 6,26 10,32
5,18 8,81 7,25 14,21
5,87 0 8,63 3,64
7,95 5,42 8,24 6,71
9,74 10,66 10,99 5,91
1,64 7,32 8,4 15,13
4,42 4,13 5,74 8,56
3,79 1,65 7,48 6,55
6,77 6,67 10,22 10,74
22,78 15,42 9,75 9,83
7,57 4,23 8,38 7,37
6,41 0 6,84 6,36
0,56 7,32 3,92 9,57
10,34 4,77 11,05 5,8
3,3 4,35 6,15 8,23
3,86 13,94 8,32 12,74
12,6 155,29 10,45 7,39
175,86 10,24
Median
0 6,075 6,67 7,94 8,35 8,56
IL-5 IL-6
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
0 1,8 2,76 0 7,68 8,79
0 2,88 3,68 0 21,4 11,34
2,1 2,98 2,35 11,52 11,24 10,89
2,81 0 2,93 4,71 0 8,86
2,4 0 3,75 13,91 6,69 11,1
2,93 8,72 10,29 25,74
2,93 0 15,81 0
2,71 2,32 13,63 7,79
3,47 1,7 12,85 23,1
0 6,59 5,16 27,56
1,33 2,74 6,99 9,88
1,51 1,75 12,82 7,06
2,47 3,49 30,17 10,96
1,56 2 14,75 9,49
1,78 0,95 18,28 9,91
2,2 0 57,19 0,64
0 2,64 0 14,26
2,13 1,98 17,29 8,2
1,13 2,15 9,67 11,48
1,41 6,33 26,52 28,88
9,79 2,2 51,68 360,55
3,56 406,27
Median
2,1 1,965 2,35 4,71 13,24 10,89
IL-7 IL-8
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
0 10,98 12,32 0 9,46 81,42
0 12,19 13,98 2,33 28,78 15,19
8,98 7,53 9,83 10,48 41,56 12,84
6,77 0 10,71 9,59 10,99 14,5
7,67 0 16,97 9,71 4,5 16,41
11,75 20,6 82,15 27,49
16,45 0 19,53 0
15,79 11,82 31,81 12,09
9,49 9,25 66,19 10,93
3,64 18,92 7,84 25,48
6,35 5,89 104,02 46,21
12,62 10,64 16,68 13,07
14,48 11,32 828,4 17,43
8,12 13,55 42,52 16,81
9,59 7,29 120,36 22,38
14,64 0 55,26 4,56
0 13,29 33,87 74,39
18,47 9,8 50,17 33,48
15,6 10,07 8,65 34,61
12,42 19,15 240,03 252,05
23,97 12,09 152,81 49,73
19,08 26,47
Median
6,77 11,97 11,32 9,59 37,715 17,43
IL-9 IL-10
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
14,13 34,14 52,46 0 6,3 7,71
5,35 43,39 57,29 0 5,62 5,81
25,76 52,84 54,83 3,88 3,8 4,66
19,63 45,28 376 5,65 0 5,23
17,17 14,45 37,21 2,34 0 5,98
60,14 95,69 7,73 9,54
30,79 0 4,49 0
43,39 32,5 6,31 4,08
52 34,81 3,05 3,18
28,36 98,79 1,16 10,45
25,91 46,58 7,32 6,93
35,04 28,56 5,16 3,16
52,69 60,37 5,98 4,1
32,27 36,91 3,83 5,19
177,78 278,63 4,04 3,08
38,94 18,88 7,1 0
18,88 35,26 0 4,72
49,17 28,86 7,29 4,63
64,78 35,26 4,55 3,33
78,58 38,56 4,43 10,68
21,51 31,23 13,56 7,16
37,36 9,22
Median
17,17 41,165 37,21 2,34 4,855 4,72
IL-12 IL-13
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
27,77 38,17 45,66 1,84 11,42 20,61
16,02 15,48 18,06 1,62 5,93 10,9
22,6 26,77 23,37 6,41 4,68 5,57
36,2 4,49 24,36 6,36 0,19 7,87
15 29,58 46,29 3,49 2,67 9,71
37,37 44,09 20,31 20,22
26,04 0 5,43 0
43,57 22,33 10,81 11,01
31,45 27,18 4,92 4,32
39,12 45,66 3,76 21,7
44,09 31,27 6,33 11
38,36 23,05 5,38 5,22
40,91 25,04 6,7 6,78
36,29 44,28 4,23 5,93
21,08 23,32 6,94 4,32
38,17 15,44 7,36 1,64
6,29 47,72 0,08 8,88
49,99 20,19 8,19 5,01
23,5 10,88 5,04 3,8
20,63 52,55 6,33 6,51
52,4 53,9 8,91 7,94
68,4 9,44
Median
22,6 36,83 25,04 3,49 6,13 6,78
IL-15 IL-17
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
0 18,38 20,72 24,77 26,12 35,57
0 6,78 11,75 25,76 64,36 67,83
11,39 5,62 13,11 51,11 57,91 58,41
0 0 14,04 35,39 24,2 49,38
22,11 0 8,52 49,26 25,9 56,43
24,48 15,89 41,11 84,11
23,62 0 36,8 16,56
30,55 33,65 45,92 34,16
17,88 20,5 50,74 29,55
0 18,01 49,6 86,22
14,77 14,08 26,79 42,84
8,24 0 47,65 29,37
7,96 7,53 65,1 63,86
24,56 19,11 56,55 59,4
8,76 9,22 49,5 35,33
19,24 0 45,43 22,8
0 17,79 36,27 49,13
23,19 0 59,71 32,62
0 13,29 26 37,42
9,94 31,98 33,11 55,25
20,63 325,88 31,52 49,94
442,06 60,39
Median
0 12,355 14,04 35,39 45,675 49,13
Eotaxin FGF
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
64,87 109,57 303,48 10,11 8,46 10,19
58,94 0 60,49 9,92 27,95 27,79
122,31 0 52,1 18,13 16,02 18,36
120,59 33,38 40,91 4,34 6,77 11,08
307,65 110,82 71,73 10,43 12,58 24,03
321,24 95,66 12,84 37,85
79,22 62,16 23,97 6,36
173,93 165,69 26,96 17,5
53,73 85,38 27,95 23,81
120,96 97,23 25,44 40,21
11,27 50,76 18,24 23,3
51,65 75,49 17,5 8,52
40,53 31,85 27,68 27,07
43,67 42,75 13,01 19,26
49,48 38,6 22,41 18,81
167,72 256,96 22,08 9,52
36,13 64,99 50,67 30,37
135,4 50,08 32,98 21,57
21,07 46,55 20,56 21,29
0 114,19 22,08 36,55
66,79 1124,1 40,05 26,52
1447,39 40,53
Median
120,59 52,69 64,99 10,11 22,245 21,57
G-CSF GM-CSF
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
10,52 12,71 16,12 0 29,16 16,08
3,81 28,99 23,26 0 56,36 27,02
20,95 18,06 22,68 0 2,71 0
16,12 6,38 16,7 0 0 39,38
16,22 13,74 24,69 0 0 0
18,45 32,79 26,43 58,82
17,86 2,04 1,32 0
21,63 18,25 31,03 28,2
22,11 13,98 91,63 96,9
18,88 35,53 2,4 81,86
12,42 16,7 43,33 45,67
16,9 11,63 8,07 0
19,22 19,99 98,14 0
18,06 28,32 15,01 20,7
19,8 11,43 60,19 47,87
19,6 6,4 82,2 0
10,11 14,37 5,68 88,84
20,86 11,43 117,7 17,09
11,43 17,86 125,49 7,56
26,7 20,57 0 133,43
32,41 17,57 79,53 119,84
24,6 167,34
Median
16,12 18,665 17,57 0 30,095 27,02
IFN-g MCP-1
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
60,28 88,53 134,2 7,25 128,55 249,23
47,59 200,77 158,97 7,59 145,19 167,51
118,31 152,8 169,37 53,31 66,95 75,5
113,95 38,1 128,44 36,62 38,04 178,8
235,51 74,57 176,43 46,73 28,85 91,67
140,9 284,47 263,03 84,96
117,83 25,48 84,13 12,16
106,66 99,83 148,24 202,21
163,7 287,65 91,53 83,37
120,8 311,66 18,92 86,98
96,4 127,47 74,32 76,31
91,48 79,61 64,06 67,02
193,77 166,06 112,3 115,61
122,66 147,57 42,18 28,48
104,23 95,42 84,59 79,86
115,89 50,76 214,78 46,92
53,93 223,51 15,8 113,19
279,47 119,76 126,26 84,52
86,55 123,14 161,24 41,42
126,51 384,29 42,93 105,76
587,99 2885,15 63,79 309,75
3890,79 255,2
Median
113,95 119,315 147,57 36,62 84,36 84,96
MIP-1a MIP-1b
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
0 2,37 4,25 30,82 42,83 77,58
0 5,47 5,95 27,41 82,28 90,38
5,12 4,6 3,84 62,86 115,86 112,6
3,41 0 5,3 134,65 48,59 83,04
3,47 0 6,1 102,78 27,54 55,79
4,48 13,28 77,16 107,96
5,62 0 104,62 44,12
5,22 4,48 147,26 140,96
6,49 5,3 90,23 49,03
4,08 11,87 74,68 99,13
5,35 5,04 152,79 160,22
5,62 3,64 93,11 91,04
16,24 6,99 345,43 115,42
6,04 5,41 156,01 124,02
5,22 6,21 153,19 85,65
6,18 0 115,72 33,84
17,38 8,42 28,22 119,1
11,2 4,02 114,38 90,57
3,93 4,55 106,27 110,52
5,85 9,01 133,15 131,67
11,92 5,54 127,19 54,54
5,88 48,08
Median
3,41 5,545 5,3 62,86 105,445 91,04
RANTES TNF-a
Healthy CAPS before CAPS after Healthy CAPS before CAPS after
2610,32 2911,63 2660,65 0,37 21,08 50,08
2426,89 2872,49 2794,62 0 68,95 58,99
2612,28 2856,9 2699,32 41,51 54,36 61,66
2508,67 4736,65 2868,92 0 0 44,01
2462,17 5963,24 2785,43 64,33 2,49 68,24
2699,46 2868,77 63,44 64,68
2810,45 2722,64 36,5 0
2730,06 2780,4 19,64 22,7
2903,58 2865,22 34 64,68
3575,08 2837,17 12,56 76,77
2807,3 2880,41 35,07 28,8
2813,9 2713,49 39,72 21,26
2928,64 2594,49 39,72 29,7
2832,16 2752,59 59,7 80,32
2713,06 1759,26 38,65 20,9
2614,7 3044,52 44,55 6,08
3164,53 2686,52 2,2 57,38
2755,2 2832,46 76,42 34
2836,26 2577,93 37,93 34
2615,24 2718,04 31,13 122,84
2766,88 2803,86 181,8 2095,04
2708,37 2144,88
Median
2508,67 2823,03 2780,4 0,37 38,29 50,08
VEGF
Healthy CAPS before CAPS after
78,18 254,53 225,04
43,21 121,06 91,02
95,11 132,18 141,15
128,16 47,3 117,65
46,69 174,41 332,96
230,69 215,43
156,02 40
350,46 182,47
148,27 115,22
178,16 190,36
265,92 206,23
279,48 130,78
256,77 99,55
147,15 154,24
162,91 113,43
301,76 79,4
63,8 325,49
304,29 115,85
169,47 63,54
172,28 278,92
272,22 345,58
485,35
Median
78,18 176,285 141,15
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SUMMARY
Despite continuous contact with fungi, immuno-
competent individuals rarely develop pro-inflamma-
tory antifungal immune responses. The underlying
tolerogenic mechanisms are incompletely under-
stood. Using both mouse models and human
patients, we show that infection with the human
pathogenic fungi Aspergillus fumigatus and Candida
albicans induces a distinct subset of neutrophilic
myeloid-derived suppressor cells (MDSCs), which
functionally suppress T and NK cell responses.
Mechanistically, pathogenic fungi induce neutro-
philic MDSCs through the pattern recognition
receptor Dectin-1 and its downstream adaptor
protein CARD9. Fungal MDSC induction is further
dependent on pathways downstream of Dectin-1
signaling, notably reactive oxygen species (ROS)
generation as well as caspase-8 activity and
interleukin-1 (IL-1) production. Additionally, exoge-
nous IL-1b induces MDSCs to comparable levels
observed during C. albicans infection. Adoptive
transfer and survival experiments show that MDSCs
are protective during invasive C. albicans infection,
but not A. fumigatus infection. These studies define
an innate immune mechanism by which pathogenic
fungi regulate host defense.
INTRODUCTION
At mucosal sites, the human immune system is faced continu-
ously with microbes, rendering fine-tuned immune responses
essential to protect against pathogenic, while maintaining
tolerance against harmless, species. This immune balance is
of particular relevance for fungi, inhaled daily as spores or pre-
sent in the gut microflora as commensal yeasts (Romani, 2011).
While immunocompetent individuals do not develop invasive
fungal infections, infections are a major problem in patients
undergoing immunosuppression, for instance, at solid organ
or hematopoietic stem cell transplantation (Garcia-Vidal et al.,
2013).
Fungi are recognized through pattern recognition receptors,
mainly C-type lectin receptors (with Dectin-1 as the prototypic
one) (Steele et al., 2005), toll-like receptors (TLRs), and pen-
traxin 3 (PTX3) (Garlanda et al., 2002; Werner et al., 2009). A
certain level of inflammation is essential to control fungal infec-
tions (Brown, 2010), but hyperinflammatory responses seem to
cause more harm than good to the host. Particularly, Th17-
driven hyperinflammatory responses have been shown to
promote fungal growth (Zelante et al., 2012), to impair fungal
clearance, and to drive tissue damage (Romani et al., 2008;
Zelante et al., 2007). Generation of reactive oxygen species
(ROS), indoleamine 2,3-dioxygenase (IDO) activity, and activa-
tion of the TIR domain-containing adaptor-inducing interferon-b
(TRIF) pathway were found to limit hyperinflammatory re-
sponses toward Aspergillus fumigatus (Romani, 2011; Romani
et al., 2009). Yet, the cellular mechanisms by which fungi
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control T cell activation and maintain tolerogenic host-path-
ogen bistability remain incompletely understood.
Myeloid-derived suppressor cells (MDSCs) are innate immune
cells characterized by their capacity to suppress T cell re-
sponses (Gabrilovich and Nagaraj, 2009). MDSCs comprise a
neutrophilic and amonocytic subset. While the functional impact
of MDSCs in cancer is established, their role in host-pathogen
interactions is poorly defined. We hypothesized that fungal
infections induce MDSCs that modulate disease outcome.
RESULTS
We analyzed the effect of the human-pathogenic fungi
A. fumigatus andC. albicans on human immune cells and noticed
the appearance of a cell population that was different from
monocytes (CD14!), and expressed the myeloid markers
CD33+, CD11b+, CD16+, and CXCR4 (Figures 1A and S1A).
Fungi-induced myeloid cells strongly suppressed both CD4+
and CD8+ T cell proliferation in a dose-dependent manner
(Figure 1B), which defines MDSCs. Fungi-induced MDSCs also
suppressed innate natural killer (NK) cell responses, without
affecting cell survival (Figure S2). In contrast to growth factor-
induced MDSCs, fungi-induced MDSCs dampened Th2
responses, which play essential roles in fungal asthma (Kreindler
et al., 2010) (Figure S1B). We quantified MDSCs in patients
with invasive fungal infections and challenged mice with
A. fumigatus or C. albicans. MDSCs accumulated in both
A. fumigatus- and C. albicans-infected patients compared to
healthy and disease control patients without fungal infections
(Figure 1C). Murine studies further showed that systemic or pul-
monary fungal challenge with C. albicans (invasive disseminated
candidiasis) or A. fumigatus (pulmonary aspergillosis), as the
clinically relevant routes of infection, dose-dependently trig-
gered the recruitment of MDSCs in both immunocompetent
and immunosuppressed conditions, with a stronger MDSC
induction seen in immunocompetent animals (Figures 1D and
S1C). MDSCs expressed neutrophilic markers in both man and
mice, resembling the neutrophilic subtype of MDSCs (Rieber
et al., 2013), while monocytic MDSC subsets were not induced
(Figure S1D). Fungi-induced MDSCs functionally suppressed
T cell proliferation (Figure 1C), while autologous conventional
neutrophils failed to do (Figure S1E).
We adoptively transferred T cell-suppressive neutrophilic
MDSCs and monitored their impact on survival in fungal infec-
tion. While a single dose of adoptively transferred MDSCs was
protective in systemic C. albicans infection, MDSCs had no
impact on A. fumigatus infection (Figure 1E). Septic shock deter-
mines mortality in candidiasis (Spellberg et al., 2005), and the
interplay of fungal growth and renal immunopathology was
shown to correlate with host survival (Lionakis et al., 2011,
2013; Lionakis and Netea, 2013; Spellberg et al., 2003). Adop-
tively transferred MDSCs dampened renal T and NK cell activa-
tion and systemic Th17 and TNF-a cytokine responses (Figures
S1F and S1G). Conversely, supplementing IL-17A dampened
the MDSC-mediated protective effect (Figure 2A). Besides these
immunomodulatory effects, MDSCs might also act directly anti-
fungal, as our in vitro studies showed that they can phagocytose
and kill fungi (Figure 2B). However, direct antifungal effects could
hardly explain the beneficial effect of MDSCs in candidiasis: (i)
adoptively transferred MDSCs had no effect on fungal burden
in vivo (Figure 2A), (ii) inhibition of phagocytosis only partially
diminished the protection conferred by MDSCs (Figure 2A),
and (iii) MDSCs were exclusively protective in immunocompe-
tent mice (C. albicans infection model), with no effect in immuno-
suppressed (neutropenic) mice (A. fumigatus infection model).
The potency of A. fumigatus to induce MDSCs was most
pronounced for germ tubes and hyphae, morphotypes charac-
teristic for invasive fungal infections (Figure 1A) (Aimanianda
et al., 2009; Hohl et al., 2005; Moyes et al., 2010). The MDSC-
inducing fungal factor was present in conditioned supernatants
and was heat resistant (Figure 3A), pointing to b-glucans as the
bioactive component. We therefore focused on Dectin-1 as
b-glucan receptor and key fungal sensing system in myeloid
cells. Fungi-induced MDSCs expressed Dectin-1, and blocking
Dectin-1 prior to fungal exposure diminished the MDSC-
inducing effect, while blocking of TLR 4 had no effect (Figures
3B and S3). Furthermore, Dectin-1 receptor activation mimicked
the generation of neutrophilic MDSCs phenotypically and func-
tionally (Figures 3C and 3D). Dectin-1 receptor signaling was
confirmed by blocking of the spleen tyrosine kinase Syk, which
acts downstream of Dectin-1 (Figure 3B). We further used cells
from human genetic Dectin-1 deficiency and used Dectin-1
knockout mice for fungal infection models. The potential of fungi
or fungal patterns to induce neutrophilic MDSCs was diminished
in human and, albeit to a lesser extent, murine Dectin-1 defi-
ciency (Figures 3E and S1D). We analyzed the role of caspase
recruitment domain 9 (CARD9), a downstream adaptor protein
and key transducer of Dectin-1 signaling, in fungi-mediated
MDSC generation in patients with genetic CARD9 deficiency
and Card9 knockout mice. These approaches demonstrated
that CARD9 signaling was involved in fungal MDSC induction
in the human and the murine system (Figures 3E and 3F).
C. albicans induces interleukin-1 beta (IL-1b) in vitro (van de
Veerdonk et al., 2009) and in vivo (Hise et al., 2009), which is crit-
ical for antifungal immunity (Vonk et al., 2006). Recent studies
further provided evidence that IL-1b is involved inMDSC homeo-
stasis (Bruchard et al., 2013). We observed an accumulation of
intracellular IL-1b protein in CD33+ myeloid cells followed by
IL-1b release upon Dectin-1 ligand- and fungal-driven MDSC
induction (Figure 4A). IL-1b protein, in turn, was sufficient to drive
MDSC generation to a comparable extent asC. albicans did (Fig-
ure 4B). Studies in Il1r!/! mice, characterized by an increased
susceptibility toC. albicans infection, demonstrated that abroga-
tion of IL-1R signaling decreased MDSC accumulation in vivo
(Figures 4B and S4A), and IL-1R antagonism in patients with
autoinflammatory diseases decreased MDSCs (Figure S4B). As
the inflammasome is the major mechanism driving IL-1b gener-
ation in myeloid cells through caspase activities, we blocked
caspases chemically. We observed that pan-caspase inhibition
largely abolished fungi-induced MDSC generation, which was
not recapitulated by caspase-1 inhibition (Figure 4C). We there-
fore focused on caspase-8, since Dectin-1 activation was shown
to trigger IL-1b processing by a caspase-8-dependent mecha-
nism (Ganesan et al., 2014; Gringhuis et al., 2012). Indeed, fungal
MDSC induction was paralleled by a substantial increase of
caspase-8 activity, and caspase-8 inhibition diminished fungal-
induced IL-1b production (Figure 4C) and the potential of
fungi to induce MDSCs (Figure 4C). Conversely, supplementing
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Figure 1. Fungi Induce Functional MDSCs In Vitro and In Vivo
(A) Fungal morphotypes differentially induce MDSCs.
Left panel: MDSCs were generated by incubating PBMCs (5 3 105/ml) from healthy donors with medium only (negative control), or different morphotypes of
A. fumigatus (conidia, 5 3 105/ml; germ tubes, 1 3 105/ml; hyphae, 1 3 105/ml) or C. albicans (yeasts, 1 3 105/ml; hyphae, 1 3 105/ml). The x-fold induction of
MDSCs compared to control conditions is depicted. *p < 0.05.
Right panel: representative histograms of fungi-induced MDSCs (CD11b+CD33+CD14!CD16+CXCR4+).
(B) Fungi-induced MDSCs suppress T cells. The suppressive effects of CD33+-MACS-isolated MDSCs were analyzed on CD4+ and CD8+ T cell proliferation.
MDSCs were generated by incubating PBMCs (53 105/ml) from healthy donors with A. fumigatus germ tubes (13 105/ml) or C. albicans yeasts (13 105/ml) for
6 days. Different MDSC-to-T cell ratios were assessed (1:2, 1:4, 1:6, 1:8, and 1:16). The lower bar graphs represent the proliferation index compared to control
conditions as means ± SEM.
(C) MDSCs in patients with fungal infections.
Left panel: MDSCswere characterized as CD14! cells expressing CD33, CD66b, CD16, CD11b, and CXCR4 in the PBMC fraction. The gray line shows unstained
controls. MDSCs were quantified in peripheral blood from healthy controls, immunosuppressed patients without fungal infections (disease controls, n = 5), or
immunosuppressed patients with invasive fungal infections (invasive A. fumigatus infections, n = 9, and invasive C. albicans infections, n = 6). *p < 0.05.
Right panel: representative CFSE stainings, showing the effect of MDSCs isolated (MACS) from patients with invasive A. fumigatus infections (left) or invasive
C. albicans infections (right) on CD4+ and CD8+ T cell proliferation.
(D) Fungi induce MDSCs in mice in vivo.
Upper left panel: C57/BL6 (n = 3mice per treatment group) or BALB/c (n = 4mice per treatment group) wild-typemice were not infected (white bars) or challenged
intranasally with 1 3 104 (light gray bar) or 1 3 106 (dark gray bar) A. fumigatus conidia for 3 days. On the fourth day, a bronchoalveolar lavage (BAL) was
performed, and CD11b+Ly6G+ MDSCs were quantified by FACS. The x-fold induction of CD11b+Ly6G+ MDSCs in the BAL compared to control non-infected
conditions is depicted. *p < 0.05.
Upper right panel: C57BL/6 mice were not infected (white bars) or injected via the lateral tail vein with 2.5 3 105 (light gray bar) or 5 3 105 (dark gray bar)
blastospores of C. albicans. On the fifth day, mice were sacrificed, and CD11b+Ly6G+ MDSCs in the spleen were quantified by FACS. The x-fold induction of
CD11b+Ly6G+ MDSCs in the spleen compared to control non-infected conditions is depicted. n = 5 mice per treatment group. *p < 0.05.
Lower panel: bonemarrow-isolated murine CD11b+Ly6G+MDSCswere co-cultured for 3 days with T cells (CD4+ splenocytes) at a 1:2 (MDSCs:T cell) ratio. T cell
proliferation was analyzed using the CFSE assay with and without MDSCs.
(E) Adoptive transfer of MDSCs modulates survival in fungal infection. For adoptive transfer experiments, CD11b+Ly6G+ MDSCs were isolated from the bone
marrow of BALB/c mice by MACS and checked for T cell suppression. In (A)–(D) bars represent means ± SEM.
Upper panel: adoptive MDSC transfer was performed by intravenous (i.v.) injection of 53 106MDSCs per animal. Sevenmice receivedMDSCs, while sevenmice
served as non-MDSC control animals. A total of 2 hr after the MDSC transfer, mice were i.v. injected with 13 105 blastospores ofC. albicans. Mice were weighed
daily and monitored for survival and signs of morbidity.
Lower panel: for invasive pulmonary A. fumigatus infection survival studies, mice were immunosuppressed by treatment with cyclophosphamide, and MDSC
transfer was performed by i.v. injection of 43 106MDSCs per animal. Five mice received MDSCs, while five mice served as non-MDSC control animals. After the
MDSC transfer, mice were challenged intranasally with 2 3 105 A. fumigatus conidia and were monitored for survival.
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IL-1b partially restored the abrogated MDSC generation upon
caspase-8 inhibition (Figure S4C).
ROS are key factors in MDSC homeostasis (Gabrilovich and
Nagaraj, 2009) and act downstream of Dectin-1 (Gross et al.,
2009; Underhill et al., 2005). Therefore, we tested the involve-
ment of ROS for fungal Dectin-1 ligand-induced MDSC genera-
tion using chemical inhibitors and cells from human CGD
patients with ROS deficiency. These studies demonstrated that
ROS contributed substantially to fungal MDSC induction (Fig-
ure 4D). Next, we investigated the interaction between ROS,
caspase-8, and IL-1b and found that ROS inhibition dampened
caspase-8 activity in response to fungi (Figure S4D). IL-1b, in
turn, induced ROS production during MDSC culture, suggesting
a positive feedback loop between caspase-8, IL-1b, and ROS in
MDSC generation (Figures S4E and S4F).
DISCUSSION
While the complete genetic deletion of pro-inflammatory cyto-
kines, particularly TNF-a, IL-1a/b, or IFN-g, increases disease
susceptibility in invasive fungal infections (Lionakis and Netea,
2013; Cheng et al., 2012; Gow et al., 2012; Netea et al., 2008,
2010), excessive inflammation causes collateral damage to the
host (Carvalho et al., 2012; Romani et al., 2008), indicating that
efficient protection against fungi requires a fine-tuned balance
between pro-inflammatory effector and counter-regulatory im-
mune mechanisms. Fungal infection induces an immunosup-
pressive state, and in murine models CD80+ neutrophilic cells
have been shown to be importantly involved in this process
(Mencacci et al., 2002; Romani, 2011; Romani et al., 1997). By
combining human and murine experimental systems, we extend
this concept by providing evidence for an MDSC-mediated
mechanism by which fungi modulate host defense, orchestrated
by Dectin-1/CARD9, ROS, caspase-8, and IL-1b. This effect
seems to be specific for neutrophilic MDSCs, since monocytic
MDSCs were unchanged under our experimental conditions
and were previously found to be downregulated by b-glucans
in tumor-bearing mice (Tian et al., 2013).
C. albicans and A. fumigatus infections differ substantially with
respect to T cell dependency and organ manifestation (Garcia-
Vidal et al., 2013). Our finding that neutrophilic MDSCswere pro-
tective in a murine model of systemic C. albicans infection, but
had no effect on pulmonary A. fumigatus infection, underlines
this disparity and suggests MDSCs as a potential therapeutic
approach in invasive C. albicans, rather than A. fumigatus infec-
tions. The MDSC-mediated effect was associated with down-
regulated NK and T cell activation, and Th17 responses and
supplementing IL-17A in vivo could, at least partially, dampen
the protective effect of MDSCs. Based on previous studies
showing that NK cells drive hyperinflammation in candidiasis in
immunocompetent mice (Quintin et al., 2014) and that IL-17 pro-
motes fungal survival (Zelante et al., 2012), we speculate that
MDSCs in fungal infections could act beneficial for the host
by dampening pathogenic hyperinflammatory NK and Th17 re-
sponses (Romani et al., 2008; Zelante et al., 2007). Accordingly,
enhancing neutrophilic MDSCsmay represent an anti-inflamma-
tory treatment strategy for fungal infections, particularly with
C. albicans.
Recent studies put the gut in the center of immunotolerance.
Dectin-1 was found to control colitis and intestinal Th17 re-
sponses through sensing of the fungal mycobiome (Iliev et al.,
2012). The immunological events downstream of Dectin-1 and
their functional impact on Th17 cells remained elusive. Our re-
sults demonstrate that fungal Dectin-1/CARD9 signaling induces
MDSCs todampenTcell responses andsuggest that the immune
homeostasis in the gut could be modulated by fungal-induced
A
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Figure 2. Antifungal Functions
(A) In vivo.
Left panel: survival in the invasive C. albicans
infection model after adoptive MDSC transfer.
Before adoptive transfer, isolated MDSCs were
pretreated with cytochalasin D (CytD, 1 mg/ml,
green line) or with recombinant mouse IL-17A
protein (5 mg/mouse, red line).
Right panel:C. albicansCFUs in kidneys of BALB/c
mice 5 days after adoptive transfer of MDSCs.
Bars represent means ± SD.
(B) In vitro.
Left panel: 1 3 106 human MDSCs were co-
cultured with 13 105 serum opsonized C. albicans
(10:1 ratio) for 3 hr at 37"C in RPMI. Serial dilutions
were performed of the cell suspension, and 100 ml
was plated onto YPD agar plates containing peni-
cillin and streptomycin. Plates were incubated for
24–48 hr at 37"C, and CFU were enumerated.
Middle and right panels: phagocytic capacity of
human and murine MDSCs. Middle panel; upper
(purple) FACS plots, isolated human granulocytic
MDSCs (low-density CD66b+CD33+ cells) were co-
cultured with or without GFP-labeled C. albicans
(CA) spores (MOI = 1) in RPMI medium at 37"C for
90 min. Lower (red) FACS plots, isolated mouse granulocytic CD11b+Ly6G+ MDSCs were co-cultured with or without GFP-labeled C. albicans spores (MOI = 4)
in RPMI medium at 37"C for 90 min. Representative dot blots are shown.
Right panel: GFP expression/fluorescence of MDSCs was analyzed by FACS and is given in the right panel as percentage of GFP+ MDSCs.
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MDSCs. Beyond fungi, the Dectin-1/CARD9 pathway has been
involved in bacterial and viral infections (Hsu et al., 2007),
suggesting that this mechanism could play a broader role in
balancing inflammation at host-pathogen interfaces.
EXPERIMENTAL PROCEDURES
Fungal Strains and Culture Conditions
A. fumigatus ATCC46645 conidia were incubated in RPMI at RT for 3 hr at
150 rpm to become swollen. Alternatively, conidia were cultured in RPMI over-
night at RT, followed by germination in RPMI either at 37"C for 3 hr at 150 rpm
to become germ tubes or at 37"C for 17 hr at 150 rpm to become hyphae.
C. albicans SC5314 was grown on SAB agar plates at 25"C. One colony
was inoculated and shaken at 200 rpm at 30"C in SAB broth overnight. To
generate hyphae, live yeast forms of C. albicans were grown for 6 hr at 37"C
in RPMI 1640. Killed yeasts and hyphae were prepared by heat treatment of
the cell suspension at 95"C for 45 min or by fixing the cells for 1 hr with 4%
paraformaldehyde followed by extensive washing with PBS to completely
remove the fixing agent. The C. albicans-GFP strain TG6 was pre-cultured at
30"C, 200 rpm overnight in YPD medium.
Generation, Isolation, and Characterization of MDSCs
Neutrophilic MDSCs in peripheral blood were quantified based on their lower
density and surface marker profiles as published previously (Rieber et al.,
2013). Human MDSCs were generated in vitro according to a published
protocol (Lechner et al., 2010). Murine MDSCs were characterized by
CD11b, Ly6G, and Ly6C. Flow cytometry was performed on a FACS Calibur
(BD Biosciences). Human and murine MDSCs were isolated using MACS
(MDSC Isolation Kit; Miltenyi Biotec).
T Cell Suppression Assays
T cell suppression assays were performed as described previously (Rieber
et al., 2013) using the CFSE method according to the manufacturer’s protocol
(Invitrogen).
Mouse Infection with A. fumigatus and C. albicans
Invasive C. albicans infection was established by IV injection in immunocom-
petent mice, whereas A. fumigatus infection was established by intranasal
challenge in immunosuppressed mice. CD11b+Ly6G+ and CD11b+Ly6C+
cells in the spleens, BAL, and kidneys were quantified by FACS. For adoptive
transfer experiments, CD11b+Ly6G+ MDSCs were isolated by MACS and
transferred by IV injection of 4 or 5 3 106 MDSCs per animal.
A B C D
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Figure 3. Fungi Induce MDSCs through a Dectin-1-, Syk-, and CARD9-Mediated Mechanism
(A) Fungal factors mediating MDSC induction are heat resistant. MDSCs were generated by incubating PBMCs (5 3 105/ml) from healthy donors with medium
only (negative control), untreated, or heat-denatured (95"C, 30min) supernatants (SNT) ofA. fumigatus germ tubes (4%) for 6 days. The x-fold induction ofMDSCs
compared to control conditions is depicted. *p < 0.05 versus control conditions.
(B) Dectin-1 and Syk are involved in fungal MDSC induction. MDSCs were generated in vitro by incubating isolated PBMCs (5 3 105 cells/ml) with A. fumigatus
germ tubes (1 3 105/ml), hyphae (1 3 105/ml), and C. albicans yeasts (1 3 105/ml) for 6 days. Where indicated, PBMCs were pretreated for 60 min with anti-
Dectin-1 blocking antibody (15 mg/ml), soluble WGP (1 mg/ml), and a Syk inhibitor (100 nM). *p < 0.05 blocking versus unblocked conditions.
(C) Dectin-1/CARD9 ligands mimic fungal MDSC induction. MDSCs were generated in vitro by incubating isolated PBMCs with the Dectin-1/CARD9 ligands
zymosan depleted (10 mg/ml), dispersible WGP (20 mg/ml), or curdlan (10 mg/ml). p < 0.05 versus control conditions.
(D) Dectin-1/CARD9 ligands induce functional MDSCs. The suppressive effects of CD33+-MACS-isolated MDSCs were analyzed on CD4+ and CD8+ T cell
proliferation (CFSE polyclonal proliferation assay). MDSCs were generated by incubating PBMCs (5 3 105/ml) from healthy donors with zymosan depleted
(10 mg/ml) or dispersible WGP (20 mg/ml). MDSC, T cell ratio was 1:6.
(E) Fungal MDSC induction in patients with genetic Dectin-1 or CARD9 deficiency.
Left panel: MDSCswere generated in vitro by incubating isolated PBMCs (53 105 cells/ml) from healthy controls (n = 12), an individual with Dectin-1 deficiency, or
patients with CARD9 deficiency (n = 2) with the Dectin-1/CARD9 ligands zymosan depleted (10 mg/ml) or dispersible WGP (20 mg/ml).
Right panel: MDSCs were generated in vitro by incubating isolated PBMCs (53 105 cells/ml) from healthy controls (n = 12), an individual with genetically proven
Dectin-1 deficiency, or patients with CARD9 deficiency (n = 2) with different fungal morphotypes (1 3 105 cells/ml) for 6 days.
(F) CARD9 is involved in fungi-induced MDSC recruitment in vivo. Card9!/! mice and age-matched wild-type mice were challenged intranasally with 1 3 106
A. fumigatus conidia for 3 days. On the fourth day, a BAL was performed, and CD11b+Ly6G+ MDSCs were quantified by flow cytometry. In (B), (C), and (E) bars
represent means ± SEM.
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Figure 4. Fungal MDSC Induction Involves IL-1b, Caspase-8, and ROS
(A) Intracellular accumulation and release of IL-1b.
Left panel: gating strategy for intracellular cytokine staining. IL-1b was analyzed in CD33+ myeloid cells using intracellular cytokine staining and flow cytometry.
Zymosan depleted (20, 100, and 500 mg/ml) and WGP dispersible (20, 100, and 500 mg/ml) were used for 1 hr to stimulate cytokine production.
Middle panel: leukocytes isolated from healthy donors (n = 4) were left untreated (empty circles) or were treated for 1 hr with increasing concentrations of
zymosan, WGP, A. fumigatus germ tubes, or C. albicans yeasts (each at 23 105/ml and 13 106/ml). IL-1b synthesis in CD33+ cells was analyzed by intracellular
cytokine stainings by flow cytometry. *p < 0.05 versus control/untreated conditions.
Right panel: co-culture supernatants were collected after incubating isolated PBMCs (5 3 105 cells/ml) with medium only (white bar), A. fumigatus germ tubes
(1 3 105 cells/ml), or C. albicans yeasts (1 3 105/ml) for 3 days. IL-1b was quantified by ELISA. *p < 0.05 versus medium control conditions.
(B) IL-1b signaling is involved in fungal-induced MDSC generation.
Left panel: MDSCs were generated in vitro by incubating isolated PBMCs (5 3 105 cells/ml) with C. albicans yeasts (1 3 105/ml) or recombinant human IL-1b
protein (0.01 mg/ml) for 6 days. *p < 0.05.
Right panel: MDSCs (CD11b+Ly6G+) were quantified in spleens from Il1r!/! and age-matched WT mice 2 days after i.v. infection with 1 3 105 blastospores of
C. albicans. *p < 0.05.
(C) Fungal MDSC generation involves caspase-8. MDSCs were generated in vitro by incubating isolated PBMCs (5 3 105 cells/ml) with C. albicans yeasts
(13 105/ml) for 6 days with or without pretreatment (where indicated) with the pan-caspase inhibitor Z-VAD-FMK (10 mM), the caspase-1 inhibitor Z-WEHD-FMK
(50 mM), or the caspase-8 inhibitor Z-IETD-FMK (50 mM). IL-1b protein levels were quantified in cell culture supernatants by ELISA (note: two values were below
detection limit). Caspase-8 activity was quantified in cell lysates using a luminescent assay. *p < 0.05.
(legend continued on next page)
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Abstract
Chitin, after cellulose, the second most abundant biopolymer on earth, is a key component of insects, fungi, and
house-dust mites. Lower life forms are endowed with chitinases to defend themselves against chitin-bearing pathogens.
Unexpectedly, humans were also found to express chitinases as well as chitinase-like proteins that modulate immune
responses. Particularly, increased levels of the chitinase-like protein YKL-40 have been associated with severe asthma,
cystic fibrosis, and other inflammatory disease conditions. Here, we summarize and discuss the potential role of chitin,
chitinases, and chitinase-like proteins in pediatric lung diseases.
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Introduction
The role of chitin and chitinases has been firmly estab-
lished in the field of plant and microbial immunity by
demonstrating that host-derived chitinases cleave chitin
to protect against invading chitin-bearing pathogens, such
as fungi. Although mammals lack endogenous chitin or
chitin synthases, chitinases and chitinase-like proteins are
endogenously expressed in their lung and other organs.
Particularly, chitinase-like proteins have been described
as dysregulated in a variety of diseases characterized by
chronic inflammation and tissue remodeling, yet their
potential role for humans has just recently begun to
evolve [1,2]. Chitin is a major component of a variety of
allergy-triggering environmental components, including
house-dust mites or fungal spores, and fungal asthma
is increasingly appreciated as an under-diagnosed dis-
ease entity [3]. Thus, an understanding of the complex
immunological and pathophysiological implications of
chitin-chitinase interactions in the human body is of
high relevance for identifying new biomarkers and thera-
peutic targets for fungal diseases and other conditions,
where chitin-coated microbial derivatives play a critical
role. Here, we provide an overview of an emerging, yet
complex field of research. Of particular interest are inter-
species differences with resulting specific nomenclatures.
Subsequent to an overall introduction of chitin, the role
of chitinases and chitinase-like proteins in pediatric lung
diseases are reviewed, leading up to a summary of ideas
how these mechanisms could be exploited to improve
diagnostics and therapeutics in lung diseases in childhood
and beyond (Figure 1).
Review
Chitin
Chitin, a polymer of N-acetylglucosamine and the second
most abundant polysaccharide in nature following cellulose,
is an essential component of fungi, house-dust mites, exo-
skeletons of crabs, shrimp and insects, parasitic nematodes,
and digestive tracts of many insects [1]. Chitin protects
these microbes from their environment, and its turnover
is regulated by biosynthesis and degradation through
endogenous chitinases.
The first immune stimulatory activity of chitin and
chitin derivatives in mammals was discovered and exten-
sively explored in the middle to late 1980s, as reviewed
recently [2,1]. These early studies clearly indicated that
chitin has important immunologic effects in vitro and
in vivo, initially highlighted by Shibata et al. who
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demonstrated that chitin activates peritoneal/alveolar
macrophages and natural killer (NK) cells to express a
number of pro-inflammatory cytokines such as interleukin-
1β (IL-1β), colony-stimulating factor (CSF), and gamma
interferon (IFN-γ) [4]. More recent studies by Reese et al.
addressed the in vivo immune effects of chitin in mice [5].
They noted that after several hours of chitin exposure,
innate immune cells were recruited to the lung and/or the
peritoneum. These studies also demonstrated that chitin
induced alternative macrophage activation and that
macrophage depletion with clodronate liposome treat-
ment prevented the recruitment of eosinophils. Van
Dyken et al. further demonstrated that fungal chitin
from asthma-associated home environments induced
allergic eosinophilic lung inflammation [6]. Collectively,
these studies strongly suggest that chitin can contribute
to the development of allergic type 2 (Th2) inflamma-
tion by activating innate immune cells. Beyond these
findings, chitin has also been proposed to serve as an
immunoadjuvant. In murine asthma models, Shibata et al.
demonstrated that orally administered chitin suppressed
the production of Th2 cytokines and IgE [7] and, when
used as an adjuvant, chitin caused similar effects as a Th1-
promoting adjuvant [8,9]. Accordingly, one can speculate
that the immune system senses chitin and that chitin can
skew the Th1/Th2 immune response in a bidirectional way.
The studies noted above suggest that the size of the
chitin fragment is a crucial determinant of the effector
responses that it elicits. This can be seen in comparisons
of large chitin polymers that are biologically inert and
intermediately sized fragments, which trigger IL-17,
IL-23, and TNF-α production [1], while even smaller
fragments enhance the production of the anti-inflammatory
cytokine IL-10. Therefore, chitin has size-dependent effects
on murine immune cell function and may bind to different
receptors in a size-dependent manner, similar to findings in
plants [10,11]. The observation that large chitin polymers
are inert, smaller fragments are pro-inflammatory, and even
smaller fragments exert an anti-inflammatory effect allows
for an interesting hypothesis regarding the importance
of the size-dependent effects of chitin in this response.
However, in all of these studies, it is difficult to rule out
that chitin preparations contained mixtures of differently
long chitin polymers or that ‘large’ chitin preparations
were containing contaminating ‘smaller’ chitin fragments.
Clearly, a more thorough study using well-defined chitin
fragments is warranted. Collectively, it is tempting to
speculate that chitin recognition by pattern recognition
receptors triggers the induction of chitinases, leading to
the generation of small-sized chitin particles that are taken
up by the host cell. Recently, fungal chitin was found to
dampen inflammation through IL-10 induction mediated
by activation of the intracellular receptors NOD2 and
TLR9 [12]. Despite these intriguing insights, the precise
molecular recognition principles of chitin perception re-
main incompletely understood. Interestingly, this hypoth-
esis is very similar to the established biology of another
polysaccharide, hyaluronin that also serves as an alarm
signal after degradation. Thus, the ability of appropriately
sized polysaccharides to induce inflammation may be a
more general principle of glycobiology [2,1]. When viewed
in combination, chitin is a central component of potential
pro-allergic microbes (e.g., Aspergillus fumigatus and
house-dust mite) and has been shown to drive Th2-
associated immune responses. Mechanisms that interfere
with chitin metabolism are therefore of high relevance
for allergic diseases and infections with chitin-bearing
pathogens such as fungi.
Chitinases and chitinase-like proteins
Chitin-degrading enzymes, known as chitinases, are pro-
duced by humans and other mammals and are part of
the 18-glycosyl-hydrolase family that encompasses both
enzymatically active chitinases and chitinase-like proteins,
the latter also termed chi-lectins, which lack enzymatic
activity. In humans, acidic mammalian chitinase (AMCase),
chitotriosidase, oviductin, and human cartilage glycoprotein
(HcGP)-39/YKL-40 and YKL-39 have been described, while
YM-1, YM-2, AMCase, oviductin, and breast regression
protein (BRP-39) have been identified in mice [13,1,14-17].
Humans express two functional chitinases, chitotriosidase
(CHIT1) and AMCase (CHIA) with an acidic pH optimum,
both able to degrade chitin polymers. In mammals, chiti-
nases [18,19] and chitinase-like proteins [20] are mainly
expressed and secreted by phagocytes (mainly neutrophils
and macrophages) and are induced at sites of inflammation,
infection, and tissue remodeling, suggesting that these pro-
teins play active roles in anti-infective defense and repair
responses. Specifically, both chitinases and chitinase-like
proteins have been linked to an alternative activation (M2)
phenotype of macrophages [21,1,22], which is found in
asthma and other chronic diseases, such as cystic fibrosis
(CF), providing a rationale for chitinases and chitinase-like
proteins to play a role in these disease conditions. While
(See figure on previous page.)
Figure 1 The proposed role of chitin, chitinases and chitinase-like proteins (CLPs) in lung diseases. Chitin is a common component of
allergy-triggering environmental components, including fungal spores and house-dust mites, which trigger an innate immune response, including
chitinases (cleaving chitin; scissors) and chitinase-like proteins (binding, but not cleaving chitin; damaged scissors). Chitinases and chitinase-like proteins
are mainly secreted by neutrophils, alternatively activated macrophages (M2 macrophages) and epithelial cells. The interplay of M2 macrophages,
neutrophils, and epithelial cells drives inflammation and remodeling in chronic lung diseases, particularly asthma, cystic fibrosis, and COPD.
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chitotriosidase is used as disease biomarker for Gaucher
disease, a disease characterized by the accumulation of
lipid-laden macrophages, acidic mammalian chitinase
has been linked to allergic asthma and hypersensitivities
[23]. However, the major evidence for an involvement in
lung diseases exists for chitinase-like proteins. Therefore,
we will focus on their role in pediatric lung diseases in the
chapters below.
The chitinase-like protein YKL-40 and its involvement in
lung diseases
YKL-40, or also called HcGP-39 or BRP-39 in mice,
lacks measurable enzymatic chitinase activity, due to
mutations in its highly conserved putative active sites [17].
In mice, BRP-39 has been associated with cell growth,
breast cancer, and tissue remodeling. Recent evidence
from BRP-39 knock-out mice indicates that BRP-39 plays
a role in T-cell, macrophage and dendritic cell responses
as well as cell apoptosis and tissue repair [21,1]. In human
cells, HcGP-39/YKL-40 has been shown to regulate apop-
tosis/proliferation/cell survival, MAPK, and cytokine
pathways [24,2].
The first indication that YKL-40 could be linked to
human lung diseases came from a multi-center study
quantifying YKL-40 serum levels in 253 adult patients
with asthma [25]. This study showed that YKL-40 serum
levels were mainly increased in adult patients with severe
asthma and correlated with disease severity and airway
remodeling. These studies in adults were, on the one
hand, confirmed for children with severe, therapy-
resistant asthma [26], but, on the other hand, challenged
by another study [27]. Besides increased levels of YKL-40,
elevated bona fide chitinase activities were also found in
bronchoalveolar-lavage (BAL) fluids from children with
asthma [28]. YKL-40 was also found to be increased in
BAL fluid after segmental allergen challenge, indicating
local production of this chitinase-like protein in response
to allergens [29]. Gavala et al. confirmed this finding and
further demonstrated that segmental allergen challenge
also increased chitinase activities [30]. Clinically, YKL-40
serum levels remained increased in patients in spite of
long-term inhaled corticosteroids, which could imply that
YKL-40 production is resistant to current asthma treat-
ments and might represent an alternative therapeutic
target for severe asthma. YKL-40 is mainly released by ac-
tivated neutrophils [20], and neutrophilic asthma is well
known to be corticosteroid-resistant [25]. Thus, increased
YKL-40 levels may be a hallmark of neutrophilic asthma.
A follow-up study analyzing single nucleotide polymor-
phisms (SNPs) in the YKL-40/CHI3L1 gene showed a
genetic association with increased susceptibility to asthma,
increased bronchial hyperresponsiveness, and reduced
lung function [31]. The role of YKL-40/CHI3L1 SNPs for
asthma was further confirmed in a Taiwanese population
[32]. Another study found a different YKL-40/CHI3L1
variant associated with asthma [33]. Given the enigmatic
role of YKL-40, the functional importance of these vari-
ants awaits further investigation. Moreover, a Chinese
study found that YKL-40 levels were increased in asth-
matic patients and correlated with exacerbation, eosino-
phils, and immunoglobulin E [34], while a study from
Poland found increased YKL-40 levels in asthma, but no
correlation with disease severity or total IgE levels [35].
Besides a positive correlation between YKL-40 levels and
age in subjects with asthma across all age groups, Santos
et al. found no difference in circulating YKL-40 levels
among asthma severities in children nor a correlation with
IgE levels [27]. When viewed in combination, some but
not all studies support the notion that YKL-40 is increased
in severe and/or neutrophilic asthma, yet the clear rela-
tionship with age/disease progression (pediatric vs adult)
and atopy remains to be defined in future studies.
Beyond asthma, other pulmonary or lung-associated
disease conditions where YKL-40 levels were found to
be increased were chronic obstructive pulmonary disease
(COPD) [36,37], idiopathic pulmonary fibrosis [38],
tuberculous pleural effusions and pneumonia [39], small-
cell lung cancer [40], non-small-cell lung cancer [41],
bronchiolitis obliterans syndrome [42], hyperoxic acute
lung injury [43], sarcoidosis [44], allergic rhinitis [45],
and CF lung disease [46]. Despite the heterogeneity of
these disease conditions, alternative (M2) macrophage
activation is a common feature of the majority of them,
suggesting that increased YKL-40 levels reflect M2 macro-
phage polarization and disease conditions featuring M2
activation [24,22,2,47].
In CF, a chronic neutrophilic inflammatory disease
[48,49], YKL-40 BALF levels were found to reflect airway
inflammation and infection in early CF lung disease [50]
and correlated inversely with lung function in adult CF
patients, where YKL-40 levels were also found to be
increased systemically [46]. The potential role of YKL-40
for the pathogenesis of CF lung disease is further sup-
ported by findings in Scnn1b-transgenic mice, a murine
model of CF-like lung disease [51,52]. In this model,
airway-specific overexpression of the β-subunit of the
epithelial Na+ channel ENaC mimics airway surface
dehydration characteristic for CF airways and produces a
CF-like lung disease with early onset of mucus obstruc-
tion, chronic airway inflammation, slowed bacterial
clearance, and progressive structural lung damage [53].
Similar to patients with CF, levels of the murine
homologue of YKL-40, BRP-39, were significantly in-
creased in BALF and showed an inverse correlation
with pulmonary function in Scnn1b-transgenic mice
[46]. Collectively, these studies suggest that YKL-40/
BRP-39 may be implicated in the pathogenesis of chronic
airway inflammation and airflow obstruction and thus
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serve as a potential biomarker of disease severity in
patients with CF.
Recent studies in this mouse model of CF-like lung
disease also provided first mechanistic insights on how
chitinases/chitinase-like proteins (CLPs), including BRP-
39, may be upregulated in CF lung disease. These studies
demonstrated that CF-like airway surface dehydration
causing mucociliary dysfunction and mucus obstruction
[54,55] provides a robust stimulus for macrophage acti-
vation, even when Scnn1b-transgenic mice are kept in a
germ-free environment [54, 56]. More recently, a series
of gene expression studies identified signatures of alter-
natively activated macrophages (M2), including Ym1, Ym2,
and BRP-39, in whole lungs and isolated macrophages
from Scnn1b-transgenic mice [57, 58]. These results
suggest alternative macrophage activation in mucostatic
airways as a mechanism underlying elevated expression
of a range of chitinases and CLPs, even in the absence
of chitin-containing parasites or allergens, in the air-
ways of patients with CF and potentially other muco-
obstructive lung diseases. While the pathogenic role of
chitinases/CLPs in (dys)regulation of inflammation in
CF airways remains poorly understood, observations in
lungs from Scnn1b-transgenic mice demonstrate that
some proteins of the chitinase/CLP family, such as Ym1
and Ym2, are expressed at such high levels that they
precipitate and form sharp crystals often greater than
100 μm in size [54]. These may cause chronic mechan-
ical irritation and injury of airway epithelial cells and
phagocytes thus contributing to chronic airway inflam-
mation. Additionally, it is intriguing to speculate that
such crystals may activate the NLRP3 inflammasome, a
pattern recognition receptor able to trigger inflam-
mation in response to other crystalline or aggregated
endogenous substances such as cholesterol or uric acid
crystals [59,60,61].
Beyond asthma and CF, circulating YKL-40 has been
further associated with decline of lung function in the
general population and has been proposed as a bio-
marker of susceptibility to the long-term effects of
cigarette smoking [62]. Studying chitinases in New York
City firefighters after World Trade Center exposure
revealed that increased serum chitotriosidase reduced
the odds of developing pulmonary obstruction after
World Trade Center-particulate matter exposure and was
associated with recovery of lung function. The underlying
mechanisms remain unclear [63]. As chitin is a structural
component of fungi, which are well known for their role
in environmental asthma, a study investigated whether
the exposure to environmental fungi modulates the
effect of chitinases in individuals with asthma. The
study demonstrated that environmental exposure to
fungi modified the effect of CHIT1 SNPs on severe
asthma exacerbations [64].
In order to dissect the cellular sources of YKL-40 in
human airways and the mechanisms regulating YKL-40
expression, Park and coworkers identified human airway
epithelial cells as a source of YKL-40 and demonstrated
that mechanical stress potently induces CHI3L1 expres-
sion leading to increased secretion of YKL-40 protein in
an EGFR and MEK1/2-dependent pathway, suggesting
that mechanical stress contributes to enhanced YKL-40
levels in asthmatic lungs [65]. A further mechanistic study
found that YKL-40 increased the proliferation and migra-
tion of bronchial smooth muscle (BSM) cells through
PAR-2-, AKT-, ERK-, and p38-dependent mechanisms
and demonstrated that YKL-40 epithelial expression was
positively correlated with BSM mass in asthma [66]. Other
studies showed that YKL-40 induced IL-8/CXCL8 expres-
sion from bronchial epithelium via MAPK (JNK and ERK)
and NF-κB pathways [67]. Taken together, these results
suggest that YKL-40-mediated IL-8 production could be
related to BSM remodeling [68]. Further studies showed
that the allergen ovalbumin increased YKL-40 expression
in tracheal epithelial cells [69] and demonstrated that
YKL-40 increased mucin5AC production in human bron-
chial epithelial cells [70]. Collectively, these studies extend
the view that YKL-40 is mainly a marker of neutrophilic
inflammation by demonstrating modulatory effects of this
chitinase-like protein on airway epithelial cells. Despite
these intriguing insights into the biological effects of
chitinase-like proteins, their precise functional role in
biological processes and disease conditions in humans
still remains largely unclear.
Conclusions
Chitin, chitinases, and chitinase-like proteins remain
enigmatic terms for human diseases. However, after the
second look into the pathophysiology of allergic and
chronic lung diseases, these ancient‚ insect glycoprotein-
associated pathways attract high relevance as potential
biomarkers and therapeutic targets. Particularly, fungal
chitin-linked asthma is increasing, but treatment options
and successful clinical trials are scarce, necessitating fur-
ther therapeutic developments. Before those approaches
can be applied clinically, several key questions remain to
be answered:
 How is chitin recognized by the human immune
system? Is it a novel pattern recognition receptor
ligand? And if so, can this interaction be targeted
and exploited therapeutically?
 What is the primary role of enzymatically active
chitinase found in the human body? To defend
against chitin-bearing pathogens or to skew the
immune system?
 Is a dysregulation of chitin sensing or YKL-40
induction pathways associated with altered
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susceptibility for diseases like fungal asthma or
house-dust mite allergy?
 Is YKL-40 a potential biomarker of severe asthma, a
marker of neutrophilic innate immune activation, or a
marker reflecting tissue remodeling (or all of these)?
 Does YKL-40 play a causative role in these disorders?
Can YKL-40 be neutralized pharmacologically? And if
so, which diseases would benefit?
 Considering YKL-40 as a therapeutic target in human
diseases, what is the physiologic function of this
protein?
These issues remain to be solved and pave the way for
an exciting novel field in pediatric immunology, bridging a
gap between insects, fungi, immune cells, and the lung.
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